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ABSTRACT 
Anemia of Chronic Kidney Disease is associated with adverse cardiovascular and clinical 
outcomes and a reduced quality of life. Erytlu·opoiesis stimulating agents (ESAs) have 
improved anemia management and two agents are available in Canada, epoetin alfa 
(Eprex®) and darbepoetin alfa (Aranesp®). Darbepoetin requires less frequent 
administration due to a longer half-life. Epoetin and darbepoetin are considered to be 
equally effective in achieving target hemoglobin in dialysis patients but it is not clear if 
there is a cost difference. There have been few head-to-head comparisons of the two 
ESAs; most published data is from observational switch studies. 
An open label randomized controlled trial of intravenous darbepoetin alfa versus epoetin 
alfa was conducted in hemodialysis patients. Fifty patients were enrolled in the study. A 
dose stabilization run-in phase was followed by a 12 month active phase. ESAs and iron 
were dosed using a study algori thm to maintain hemoglobin within 1 00-120g/L. The 
primary outcome was the cost per patient ofESA over 12 months. Secondary outcomes 
included deviation from target ranges in anemia indices, iron dose and cost, time and 
number of dose changes required for dose stabilization, number of dose changes in the 
active phase and the dose conversion ratio. 
The median cost for epoetin over 12 months was $4179(IQR $2416-5955) and for 
darbepoetin was $2303(IQR $1178-4219) with a difference of $1876 (p=O.O 17). There 
was no significant difference in the dose or cost of iron. The median weekly iron dose 
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was 40.4mg for epoetin and 41.7mg for darbepoetin (p=0.992). There were no significant 
differences in the anemia care targets including hemoglobin: 1 08.0g/L epoetin and 
109.8g/L darbepoetin (p=0.336); serum ferritin: 848Jlg/L epoetin and 726Jlg/L 
darbepoetin (p=0.202); TSAT: 26.7% epoetin and 28.6% darbepoetin (p=0.472). 
The number of dose changes and the time required to attain hemoglobin stability in the 
run-in phase and the number of dose changes in the active phase were similar for both 
groups. The dose conversion ratio was 280:1 (95% CI 197-362:1) at the end ofthe run-in 
phase, 360:1 (95% CI 262-457: I) at the 3 month point of the active phase and 382:1 (95% 
CI 235-529:1) at the 6 month point of the active phase. 
In this study of hemodialysis patients with comparable anemia management, darbepoetin 
cost $1876 less per year per patient than epoetin. This difference represents a significant 
cost savings which would be of interest to clinicians, policy makers and payers. 
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Chapter 1 Introduction 
1.1 Anemia in ChJonic Kidney Disease 
Anemia occurs when there is a lower than normal number of circulating red blood 
cells which is usually measured by a decrease in the amount of hemoglobin in the 
blood. Anemia may be caused by nutritional deficiencies, may be drug-induced or 
may be associated with chronic diseases. 1 
Anemia is one of the earliest, most characteristic, and morbid manifestations of 
Chronic Kidney Disease (CKD) and is often present before the onset of uremic 
symptoms. It is generally a normochJomic, normocytic anemia? The severity and 
prevalence of anemia increases as CKD progresses and is present in most patients 
with a glomerular filtration rate (GFR) between 30-40mL/min, but may also occur 
with higher GFRs. Anemia of CKD is associated with left ventricular hypertrophy, 
adverse cardiovascular and clinical outcomes and a reduction in quality of life .3' 4 
While a number of factors may contribute to the development of anemia in CKD 
including iron deficiency, blood loss, inflammation, secondary hyperparathyroidism 
and shortened red blood cell survival, decreased erythropoietin production by the 
kidney is the principal cause. Erythropoiesis is the process by which red blood cells 
are produced in the body. Red blood cells are critical as they contain hemoglobin, 
which is a vital iron-containing molecule that canies oxygen between the lungs and 
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tissues. When oxygen levels are decreased in the blood, a glycoprotein hormone 
called erythropoietin is released which acts on the bone marrow to stimulate 
reticulocyte (red blood cell precursor) production. The kidney is the primary site of 
erythropoietin production (90%), with a small contribution from the liver, making it 
unique amongst the hematopoietic growth factors as it is not produced in the bone 
marrow. The kidney acts as a hematocrit meter in that it detects oxygen tension and 
extracellular volume and it regulates red cell mass through production and release of 
erythropoietin and plasma volume through excretion of salt and water. In this process, 
it maintains the hematocrit at a normal value of 45% which maximizes oxygen 
delivery to the peripheral tissues. As kidney function declines, so does the production 
of erythropoietin with subsequent progressive anemia? · 5 
1.2 Management of Anemia - Iron 
Adequate iron is essential for erythropoiesis as it is needed to produce hemoglobin. 
Iron deficiency requiring supplementation is common in hemodialysis patients. In the 
initial assessment of anemia in CKD, iron status should be assessed with serum 
ferritin (a surrogate marker for tissue iron stores) and transferrin saturation (TSAT -
represents iron which is available for erythropoiesis) with consideration of the mean 
corpuscular volume (which is a late marker of iron deficiency). It is important to note 
that interpretation of ferritin levels alone is difficult because ferritin is an acute-phase 
reactant and can be elevated for reasons other than high tissue iron stores. Some argue 
3 
that transferrin saturation is a more reliable measure as it is not influenced by 
. f1 6 m ammatory states. 
The Canadian Society of Nephrology (CSN) in their current Clinical Practice 
Guidelines recommend that in hemodialysis patients iron should be administered 
intravenously to maintain serum ferritin>200ng/mL and TSAT >20%.7 Absolute iron 
deficiency occurs when both the fenitin and TSA T are below the target values. 
Functional iron deficiency may also occur in hemodialysis patients, in which case the 
serum ferritin is above 200ng/mL (and is often in the upper end of the acceptable 
range or higher) but the TSA T is below 20%. In functional iron deficiency, there is an 
apparent inability to mobilize iron stores. 8 While the safety of administering iron 
when the serum ferritin is above 500ng/mL is not clear, there is some evidence from 
the DRIVE9 trial that when the TSA T is concomitantly low intravenous iron can 
increase the hemoglobin level, though this study was not powered to assess safety. As 
iron therapy has not been tested by large randomized trials with important clinical 
outcomes, the CSN currently recommends that the risk and benefit of continued iron 
administration when the serum ferritin level is above 800ng/mL should be carefully 
considered in each patient. 7 
In the Fall of2012, the KDIGO (Kidney Disease Improving Global Outcomes) 
Anemia Work Group published clinical practice guidelines for the management of 
anemia in CKD. 10 In these it is recommended to balance the potential benefits of iron 
therapy with risks of harm in individual patients (acute reactions and unknown long-
4 
term risks). More specifically in adult CKD patients not already on ESA or iron, they 
recommend a trial of intravenous iron if an increase in Hb is desired and the TSAT is 
:S30% and ferritin is :S500ng/mL. For adult CKD patients on ESA and not on iron, 
they recommend intravenous iron if an increase in Hb or a decrease in ESA dose is 
desired and the TSAT is :S30% and ferritin is :S500ng/mL. 
1.3 Management of Anemia - Erythropoiesis Stimulating Agents 
Erythropoiesis stimulating agents (ESAs) are proteins which stimulate erythropoiesis 
by the same mechanism as endogenous erytlu·opoietin. The development of these 
drugs was a major advance and since the first agent came to market in 1989 the 
management of anemia in CKD has improved dramatically as previously the main 
therapeutic option was red blood cell transfusions.3 When epoetin was first used 
clinically it was primarily in long-term, transfusion-dependent hemodialysis patients 
with the goal of alleviating symptoms and decreasing transfusions and potential 
transfusion complications. ESA use eventually extended to most dialysis patients with 
anemia and to stages 4 and 5 CKD patients. Complete correction of anemia was 
initially expected to be beneficial for patients with respect to left ventricular 
hypertrophy, cardiovascular outcomes, hospital admissions and death based on early 
observational studies. However, as clinical trials were conducted in large groups it 
became apparent that complete correction of anemia to normal hemoglobin levels 
does not offer cardiovascular benefits and in fact may be harmful with respect to 
increased risk of stroke, vascular access problems and hypertension with modest or 
questionable improvements in quality of life. In the recently published guidelines for 
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anemia management, KDIGO recommends that when using ESA therapy clinicians 
should consider and balance the benefit of reduced blood transfusions and anemia 
related symptoms against the risk of harm in individual patients. In addition, they 
recommend using ESAs with great caution, if at all, in CKD patients with active 
malignancy, a history of stroke, or a history of malignancy. 10 This recommendation 
was based primarily on outcomes of ESA use in the oncology population. Of note, in 
a post-hoc analysis of the TREAT study 11 ofESA use in CKD patients there was a 
significantly higher death rate from cancer in patients with a history of malignancy in 
the darbepoetin arm compared to the placebo arm. 
The current CSN Clinical Practice Guidelines state that ESAs should be used to treat 
anemia when iron stores are replete, other causes of anemia have been addressed and 
the hemoglobin is sustained below 1 OOg/L. The CSN reconm1ends a target 
hemoglobin of llOg/L, with an acceptable range of 100-120g/L.4 
With respect to anemia targets, the new KDIGO clinical practice guidelines for 
anemia management recommend that ESA therapy be initiated in adult dialysis 
patients when the Hb is between 90-1 OOg/L to avoid having the Hb fall below 90g/L. 
It is also recommended in general to not use ESAs to maintain Hb above 115g/L, and 
to never use them to increase Hb above 130g/L. The KDIGO guidelines suggest an 
individualized approach to determining targets may be necessary in some patients.10 
6 
Endogenous erythropoietin consists of a polypeptide core of 165 amino acids with 
four glycosylation sites that carry three N-linked and one 0-linked oligosaccharide 
chain. The receptor binding sites are localized at one end of the molecule, distant from 
the glycosylation sites. The three N-linked chains may contain 2-4 oligosaccharide 
branches, each terminated with a sialic acid. The 0-linked chain carries up to two 
sialic acid residues. The biologic activity of erythropoietin is largely determined by 
theN-linked carbohydrate residues. 12 
Epoetin was first marketed in 1989 and is a recombinant human erythropoietin (r-
HuEPO) which is composed of the same amino acid sequence with tlu·ee N-linked 
carbohydrate chains as endogenous erythropoietin but the glycosylation varies. There 
are two commercially available epoetin types - a (Eprex®, Procrit®) and ~ 
(Recormon®, Neorecormon®). These are produced by Chinese hamster ovary cells 
and contain a higher proportion of sialylated, acidic carbohydrate residues than 
endogenous erythropoietin. Epoetin ~ has a higher molecular weight than a and is 
available in some European and other countries but is not marketed in the U S or 
Canada. In Canada, epoetin a is available as Eprex® only. There are no significant 
clinical differences between epoetin a and ~. 1 2 
Darbepoetin alfa was approved for use in 2001 for anemia of CKD. Darbepoetin is 
also produced in Chinese hamster ovary cells. 12 It differs from epoetin in that it has a 
higher molecular weight and contains two additional N-linked carbohydrate chains 
and the increased sialylated carbohydrate content results in a longer half-life and 
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sustained biologic activity. 13 Darbepoetin has a lower binding affinity for the 
erythropoietin receptor than epoetin alfa in vitro and takes 3-5 times longer to reach 
k . 14 pea serum concentratiOns. 
Darbepoetin has a three-fold longer half life than epoetin when administered 
intravenously with half-lives of25.3 hours and 8.5 hours respectively. When given 
subcutaneously, the half-lives are 48.8 hours and 16-24 hours. 15- 17 Based on this, 
darbepoetin is administered once weekly or once every two weeks, whereas epoetin 
should be given in multiple weekly injections (most often three). 
Epoetin appears to require higher doses when it is administered less frequently. 18 It 
was found in a study in the United Kingdom of hemodialysis patients that both 
epoetin and darbepoetin could maintain hemoglobin targets when administered once 
weekly, but the dose of epoetin required was higher when given once weekly as 
compared to tlu·ee times weekly. 19 The CSN currently recommends that epoetin 
should be given tlu-ee times weekly as reduced dosing frequency may lead to 
increased dose requirements.4 
Epoetin was reported to require higher doses when administered intravenously than 
subcutaneously in a meta-analysis of27 comparative studies involving 916 
hemodialysis patients. 20 In a pharmacokinetic study of darbepoetin, it was found that 
the intravenous and subcutaneous doses are the same, and that this was likely due to 
its longer terminal half-life than epoetin. 16 In a prospective, noninferiority trial of 
8 
epoetin versus darbepoetin (IV and SC) in dialysis patients, it was fow1d that the 
intravenous and subcutaneous doses of darbepoetin did not differ over the 52 week 
study period, whereas in the epoetin group the dose requirements for subcutaneous 
administration were 22% less than for intravenous administration.21 
1.4 Dose Conversion 
Based on peptide mass, 200 IU (international units) of epoetin a is equivalent to 1 !lg 
of darbepoetin a. 12 As a result, when darbepoetin came to market and patients were 
first converted from epoetin, it was recommended by the manufacturer to determine 
the initial darbepoetin dose based on a fixed ratio of 200:1 ( epoetin:darbepoetin)?2 
As this ratio was employed in studies it became apparent that it was not accurate in all 
dose ranges and for all indications and in most cases darbepoetin was found to be 
more potent on a protein mass basis than epoetin. A combined analysis of three 
studies in dialysis patients found that the linear relationship between epoetin and 
darbepoetin doses becomes curvilinear at higher doses of epoetin, particularly above 
7000 units weekly when less darbepoetin was required than the 200:1 ratio would 
predict. The ratio was found to continue to increase with higher epoetin doses. 1' 21 ' 23 
Several other studies found the 200:1 ratio to result in excessive darbepoetin doses.15' 
19 24
-
31 Tl. "d f . I d 1 . h. d h ' 11s ev1 ence o a nonproporttona ose re atwns 1p prompte t e 
manufacturer to develop a conversion chart in which the conversion ratios 
reconm1ended vary widely within the dose categories (Table 1). It is worth noting that 
doses above 30 000 units weekly of epoetin alfa are not typically used in treatment of 
anemia of CKD, so the higher dose conversion recommendations have not been 
9 
included in this table. Also, the smallest available pre-filled syringe of darbepoetin is 
1 O~g, so a 6.25 ~Lg dose is not practically possible. 
Table 1: Aranesp® Dose Conversion Chart and Subsequent Dose Ratio Range23 
Previous Weekly Epoetin Manufacturer Dose Ratio Range 
alfa Dose (units/week) Recommended Weekly 
Darbepoetin Dose 
(~g/week) 
<2500 6.25 400:1 
2500-4999 12.5 200:1 - 400:1 
5000-10 999 25 200:1 - 440:1 
11 000-1 7 999 40 275: 1- 450:1 
18 000-33 999 60 300:1 - 567:1 
When studies have been conducted using the manufacturer' s conversion table, it has 
been found that the recommendations for higher epoetin doses resulted in inadequate 
darbepoetin doses. In one Canadian study where hemodialysis patients were switched 
from epoetin to darbepoetin it was determined that for epoetin doses above 17 000 
units weekly, the darbepoetin dose based on the conversion chart was too low and 
dose increases were required. As a result, the authors developed their own dosing 
algorithm in which epoetin doses of 7000 units weekly or less were converted using a 
200:1 ratio and epoetin doses greater than 7000 units weekly were changed using a 
300:1 ratio.32 In a small observational study of hemodialysis patients in the United 
States in which patients were converted from epoetin to darbepoetin, the conversion 
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table doses were insufficient and darbepoetin dose increases were required in 67% of 
patients. 33 
In 2004, the Centres for Medicare and Medicaid Services in the United States adopted 
a fixed conversion ratio of 330:1 for darbepoetin from epoetin. In a cost-minimization 
analysis in the hospital setting comparing epoetin alfa with darbepoetin, it was 
determined that a cost benefit with darbepoetin would only be realized in the hospital 
setting when the dose conversion ratio exceeded 257:1.34 In most regions including 
this province, Aranesp® (darbepoetin) has been priced relative to Eprex® (epoetin 
alfa) based on the 200: I protein mass ratio. As a result the dose conversion ratio is 
important in that as it increases, there are resultant cost savings with darbepoetin 
based on the current pricing structure. However, it is still unclear from the available 
evidence what the best dose conversion ratio is. 
1.5 Significance of Research and Purpose of Study 
The comparable clinical effectiveness of epoetin and darbepoetin is a major 
assumption of this cost minimization analysis. Epoetin and darbepoetin are 
considered to be equally effective in achieving target Hb in dialysis patients.35• 36 
While relative potencies may differ, there is no evidence that one ESA is more 
effective in stimulating erythropoiesis than another. 12 A number of studies have 
demonstrated that darbepoetin is effective in correcting anemia in rHuEPO na'ive 
patients and in maintaining hemoglobin levels in patients who are switched from 
epoetin. The adverse effect profiles of darbepoetin and epoetin are comparable. In 
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particular, thrombotic events including vascular access thrombosis, venous 
thrombosis and pulmonary emboli occurred in clinical studies of darbepoetin at 
frequencies similar to those seen in studies of epoetin. 13 
It is not clear if the cost associated with anemia therapy is different for patients treated 
with darbepoetin than with epoetin. Approximately 90% of hemodialysis patients 
receive ESA for anemia management and it is a costly component of care, historically 
averaging between $6000-7000 annually per patient in this province. Based on 
billings to date in 2012, it is estimated that the cost ofESA therapy in Eastern Health 
will be approximately $1 600 000 this year. In the absence of any data suggesting a 
clinical advantage of one ESA over the other, determining if a cost advantage exists 
will allow clinicians, policy makers and payers to make informed and rational 
decisions about the use of these costly resources. 
For ESAs, drug cost is directly related to drug dosage and even small differences in 
potency per unit cost of ESA can translate into large differences in costs. It was 
recommended in a review by the Canadian Agency for Drugs and Technology in 
Health (CADTH) that head-to head comparisons of epoetin and darbepoetin should be 
done. 37 As discussed later in the literature review, there have been very few head-to-
head comparisons ofthe two ESAs. Most studies have been pre- and post-conversion 
comparisons in which results are difficult to interpret and apply. Many of the studies 
were of subcutaneous administration, which was the route most commonly used in 
hemodialysis patients when epoetin first became available. This practice changed 
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rapidly when in the late 1990s an increased incidence of pure red cell aplasia was seen 
in CKD patients receiving epoetin subcutaneously. As a result it was recommended 
that the intravenous route be used in hemodialysis patients and most patients were 
switched to intravenous epoetin which remains the most commonly used route in this 
population in Canada today. It was subsequently determined that the pure red cell 
aplasia was most likely caused by the leaching of polysorbate 80 from the stopper of 
pre-filled syringes and since this has been corrected, pure red cell aplasia occurs very 
rarely with subcutaneous administration of epoetin. Despite this, the manufacturer still 
recommends the intravenous route as the preferred route in hemodialysis patients in 
the Canadian product monograph. 
To address the question of differential costs associated with anemia therapy, a cost 
minimization analysis was undertaken in an open label, parallel group, randomized 
controlled trial of intravenous darbepoetin alfa (Aranesp®) versus epoetin alfa 
(Eprex®) in hemodialysis patients. The goal was to provide stakeholders with 
evidence to choose between the two ESAs which are otherwise clinically equivalent 
to the best of our knowledge. 
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Chapter 2 Review of Literature 
2.1 Search Strategy 
To determine if a cost advantage exists for darbepoetin or epoetin in the management of 
anemia of CKD in hemodialysis patients, the ideal study design would be a parallel group 
randomized controlled trial. The study would include only hemodialysis patients, would 
involve intravenous administration only (generally the only route used in hemodialysis 
patients), would be sufficiently long to see dose stabilization with darbepoetin (at least 5-
6 months '· 15• 17• 32) and would use pre-defined dosing protocols for both ESA and iron to 
ensure a consistent approach with all subjects. 
An extensive literature search was performed in PubMed using the following search 
terms: 
• "Erythropoietin AND darbepoetin AND cost" 
• "Aranesp AND Eprex AND conversion" 
• "Erythropoietin, Recombinant (Mesh) AND darbepoetin alfa(substance 
name)AND Therapeutic Equivalency(Mesh)" 
These searches were combined using " OR" and the final yield was 128 references. The 
same search terms were used in Em base and IP A and this did not yield any additional 
references. The Cochrane database provided one reference. All abstracts were reviewed 
for relevance to the question and after eliminating those from the oncology population, 
review articles, those in pre-dialysis patients, and papers about ESA use in other areas 
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such as surgery and cardiology, there were 25 references of interest identified. These 
included 3 randomized controlled trials, 9 prospective switch studies, 6 retrospective 
switch studies, 1 cross-sectional analysis, 3 economic studies and 3 systematic reviews. 
The studies are reviewed in detail below. 
2.2 Randomized Controlled Trials 
Nissenson et al published the only randomized controlled trial comparing IV darbepoetin 
alfa to IV epoetin alfa in hemodialysis patients with drug dose as an outcome, albeit a 
secondary outcome. The study was a multicenter, randomized, double-blind, 
noninferiority trial to determine if darbepoetin was as effective in maintaining Hb as 
epoetin in CKD patients on hemodialysis. 1 From 35 centres in the United States and 5 
centres in Canada, 507 patients were randomized in a 2: 1 allocation to continue epoetin 
alfa or to switch to darbepoetin. Those randomized to darbepoetin were switched using a 
200:1 ratio ( epoetin:darbepoetin). There was a 20 week titration and stabilization period 
followed by an 8 week evaluation period. Epoetin and darbepoetin doses were adjusted by 
25% if the hemoglobin remained above or below target on 2 consecutive weekly 
assessments. Iron was dosed according to the individual unit policy to maintain TSAT 
above 20%. The primary outcome was the mean change in hemoglobin levels between 
baseline and the evaluation period and secondary outcomes included hemoglobin 
variability and drug dose. Darbepoetin was found to be as effective as epoetin in 
maintaining hemoglobin within a range of 90-130g/L throughout the study period and the 
mean changes in hemoglobin levels from baseline to the evaluation period were not 
significantly different between the two groups. There was no significant difference in 
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hemoglobin variability between the two drugs. With respect to drug doses, the authors 
state that mean doses of study drug were similar between baseline and the evaluation 
period which suggested that the 200:1 ratio used to dose darbepoetin was appropriate. 
The mean weekly dose ofepoetin was 12 706 units at baseline and 13 639 units during 
the evaluation period. The mean weekly dose of darbepoetin was 63.18 ).lg at baseline and 
54.18 ).lg during the evaluation period. The study was not designed to determine the dose 
ratio between the two drugs or if there was a difference in cost, however from baseline to 
the end there was a decrease in the darbepoetin dose and an increase in the epoetin dose. 
Molina et al conducted a prospective clinical trial in Spain to assess the effectiveness and 
safety of changing SC epoetin alfa to either IV epoetin alfa or IV darbepoetin alfa in 112 
hemodialysis patients.38 A 200:1 ratio was used to determine the darbepoetin doses and 
follow-up was for 24 weeks. The goal was to maintain hemoglobin between 11 and 
13 g/dL. The outcome measured was the resistance index which was defined as the weekly 
dose per kilogram of weight/level of hemoglobin. In the arm switched to IV from SC 
epoetin, a significant increase in the resistance index was observed with mean values of 
2.73 and 4.37 after 16 and 24 weeks respectively. In the arm switched to darbepoetin 
there was a decrease in the resistance index starting at week 8 with mean levels of0.012, 
0.018 and 0.023 at weeks 8, 16, and 24 respectively. The dose conversion factor from SC 
epoetin alpha to IV darbepoetin increased significantly to 1 :260 by week 24. 
Dolman et al published a study out of the United Kingdom in 2004 in which 217 
hemodialysis patients on SC epoetin beta were randomized to once weekly SC epoetin 
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beta (total weekly dose given once weekly) or once weekly SC darbepoetin (using a 200:1 
dose conversion ratio) 19. It was an open-label prospective trial with a predefined 9 month 
follow up period in which doses were adjusted using a computerized decision support 
system and Hb and drug doses were compared between baseline and the end of follow-up. 
The computerized system had been in place for more than a year prior to the study start 
and based on monthly hemoglobin concentrations and trends advised dose changes to 
maintain hemoglobin between 11-12g/dL. A protocol for iron dosing was used to 
maintain serum ferritin between 1 00-500~g/L. Similar hemoglobin outcomes were found 
in both groups at randomization and at the end of the study. In the per protocol analysis, 
the mean darbepoetin dose fell from 0.59 ~g /kg/week to 0.46 ~tg/kg/week which was a 
20% dose reduction. The epoetin mean dose increased from 107.5 units/kg/week to 133.2 
units/kg/week, representing a 24% increase in dose. Similar results were seen in a 
modified intention to treat analysis. Of the 217 subjects randomized, 169 completed the 
study. It was noted that dose and hemoglobin stabilization did not occur in this study until 
at least 28 weeks after conversion, suggesting a minimum follow-up period for similar 
trials is required. 
The randomized controlled trials are summarized in Table 2. While these studies were not 
designed to test the specific research question of interest, the results of these trials seem to 
indicate that the 200:1 ratio for dose conversion is likely not stable and correct in the 
hemodialysis populations studied. 
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Table 2: Randomized Controlled Tria ls 
Subjects ESA Targets (Hb, Fe) Outcomes Results 
Follow-up 
Nissenson HD IV epoetin alfa Hb 90-130g/L I 0 -mean - Equally 
US/Canada,2002 n=507 and TSAT>20% change in Hb effective in 
IV darbepoetin 2° -Hb maintaining Hb 
20 week ti tration variab il ity, - darbepoetin not 
and 8 week drug dose inferior to 
evaluation epoetin 
- Hb variability 
not different 
- Epoetin dose 
simi lar, 
darbepoeti n dose 
decreased 
Molina HD SC epoetin alfa Hb ll-13g/dL Resistance - Resistance index 
Spain, 2004 n= ll2 changed to index increased for 
IV epoetin alfa 24 weeks epoetin 
or Dose - Resistance index 
IV darbepoetin conversion decreased for 
factor darbepoetin 
- Dose conversion 
ratio I :260 at 
week 24 
Dolman HD SC epoetin ~ Hb l l-1 2g/dL Hb - Similar Hb 
UK, 2004 n=169 and Ferritin I 00- outcomes 
SC darbepoetin 500}lg/L ESA dose - Darbepoetin 
dose fe ll by 20% 
9 months - Epoetin dose 
increased by 
24% 
HD=hemodtalysts 
2.3 Prospective Switch Studies 
The term "switch study" is used in this and the subsequent section. The term refers to 
studies that examine outcomes before and after conversion of a whole population from 
one ESA to the other (also referred to as historic control or pre- and post- study). 
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Hirai et al switched 104 Japanese hemodialysis patients who were stable on IV epoetin 
alfa to IV darbepoetin using the 200:1 ratio and followed them for 52 weeks to determine 
changes in hemoglobin and darbepoetin dose?4• 39 Hemoglobin was measured every two 
weeks and darbepoetin doses were varied to maintain hemoglobin between 1 0-1 2g/dL. 
Intravenous iron supplementation was given to maintain TSAT above 20% and serum 
ferritin above 1 OOng/mL. There was no discussion of pre-defined dosing protocols. Initial 
results were published after 24 weeks of follow-up at which point they found the dose 
conversion ratio to be 1:350.5 (darbepoetin: epoetin). At 24 weeks 100 subjects remained 
in the study. After 52 weeks, 85 patients remained in the study and the final dose 
conversion ratio was found to be 1 :286.6. The initial 1 :200 conversion ratio lead to a 
rapid increase in hemoglobin in the darbepoetin group, particularly in the first 8 weeks 
and the dose of darbepoetin subsequently decreased gradually until it stabilized at 20 
weeks. The study population was divided into those with initial high and low doses of 
epoetin and diabetics and non-diabetics to determine if the findings would be different. 
Similar results were found in the diabetics and non-diabetics. Patients initially on higher 
doses of epoetin (>4500 units weekly) had a higher conversion ratio compared to those 
switching from lower doses. The authors concluded that darbepoetin may lead to reduced 
costs as compared to epoetin and that it may be more effective in resistant anemia 
because less was required in those on higher initial epoetin doses. 
Nakagawa, in a letter to the editor, 40 describes switching 26 hemodialysis patients in 
Japan from epoetin alfa to darbepoetin using the 200:1 ratio. The goal was to maintain 
hemoglobin between 1 0-11g/dL with erythropoiesis stimulating agents and iron. "Cost-
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effectiveness" is stated as the outcome measured and is defined as cost per unit (g/L) of 
hemoglobin. The final stable dose of darbepoetin was less than the dose at initiation in 
almost all patients with a savings of 34.1 %. The tota l cost of epoetin alfa from the 32nd to 
35th week of2007 and the hemoglobin in the 34th and 361h week of2007 were compared 
to the total cost of darbepoetin from the 2nd to the 5th week of 2008 along with the 
hemoglobin from the 4th and 6th week. It was determined that epoetin cost ¥3109/1 g/dL of 
hemoglobin/patient and darbepoetin cost ¥2 149/1 g/dL of hemoglobin/patient. Of note, the 
route of administration was not specified in this letter and the study was very small with 
outcome measurements over very short time periods. 
Bock, in 2007, designed a study to explicitly investigate the dose conversion ratio 
between epoetin and darbepoetin in Switzerland? 5 One hundred thirty two hemodialysis 
patients from 17 centres were enrolled and IV or SC epoetin alfa or beta was switched to 
IV darbepoetin using the 200:1 ratio. A study protocol was used for darbepoetin dosing in 
which hemoglobin was measured every two weeks and stepwise dose adjustments were 
made to maintain Hb within ± 1 g/dL of each subject 's baseline value (baseline 10.8-
13g/dL). Intravenous iron was administered as per the protocols of each individual study 
centre to maintain TSAT above 20% and ferritin above 1 OO)lg/L. Dose titration and 
stabilization took place over 20 weeks followed by a 4 week evaluation period. The 
primary endpoint was the change of darbepoetin dose between baseline and the evaluation 
period required to maintain hemoglobin within 1 g/dL of baseline value. Secondary 
endpoints included change in darbepoetin dose and change in mean hemoglobin and 
safety variables. One hundred patients completed the study and the mean final conversion 
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ratio was 1:336 (darbepoetin:epoetin) (95% CI 284-388). The mean darbepoetin dose at 
baseline was 34.7!-lg compared to 26!-lg during the evaluation period, with a continuous 
decrease in the darbepoetin dose throughout the course of the study that was most 
pronounced between weeks 5-9. A stepwise linear regression model of dose saving of 
darbepoetin versus baseline epoetin dose, route of administration, type of epoetin (alfa or 
beta) and dosing frequency found only baseline weekly epoetin dose to be significant 
after the elimination of all other variables with a curvilinear relationship between baseline 
epoetin dose and the conversion factor. 
Icardi et al published a study in 2007 out of Italy in which 25 hemodialysis patients were 
switched from IV epoetin alfa to IV darbepoetin? 6 Dose adj ustments ofESA were made 
in 25% increments when Hb fell outside of 1 0.5-12.5g/dL. Iron status was maintained 
with intravenous iron to maintain ferritin above 1 OOng/mL and TSA T above 20% as per a 
standardized dose protocol. Subjects were followed for 6 months on IV epoetin alfa 
(phase 1) then were switched using a 200: 1 ratio and fo llowed for a subsequent 12 
months (phase 2). The epoetin:darbepoetin dose ratio was evaluated and 
pharmacoeconomic analysis was performed. In phase 1 the mean weekly epoetin dose 
showed no significant variation. In phase 2 the epoetin:darbepoetin conversion factor rose 
progressively from 200-256.1: 1 at month 7 and 336.8:1 at month 12. The conversion 
translated into cost savings. This was a very small study and while 40 subjects consented, 
15 were excluded after consent for various reasons. In addition, 4 of the 25 patients 
showed relative erytlu·opoietin resistance but remained in the study. 
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Shalansky et a! aimed to assess the efficacy of of IV darbepoetin to maintain Hb 
compared to SC epoetin alfa in a Canadian study from 2003-2004.32 This was an 18 
month, open label observational study of95 hemodialysis patients who were switched to 
darbepoetin as per the manufacturer' s conversion table with some modifications (for 
available prefilled syringes and one dose category was divided into two narrower 
categories). At the time of the switch, data was collected retrospectively for 6 months and 
prospectively after the switch for 12 months, the first 6 months after the switch was a 
dose titration phase. ESA dose adjustments were made in 25% increments to maintain Hb 
between 120-135g/L. Iron was administered IV or orally to maintain TSAT 20-50% and 
serum ferritin 1 00-8001J.g/L. The primary outcome was to measure Hb to determine if 
darbepoetin was as effective in maintaining targets as epoetin. The secondary outcomes 
were to evaluate the manufacturer's recommended guidelines for conversion and to assess 
the cost implications of switching to darbepoetin. They found no significant difference in 
Hb between any of the study phases. The dose conversion ratio was calculated by 
comparing the mean weekly dose of epoetin at the time of the switch to the mean weekly 
dose of darbepoetin at each three-month interval in phase 2. Based on their results a 
dosing nomogram was developed in which all patients receiving 7000 units of epoetin 
weekly or less would be converted by the 200:1 ratio and those receiving greater than 
7000 units weekly would use 300:1 . A cost analysis was performed comparing mean 
darbepoetin usage over each time period to baseline epoetin dose, adjusted for patient 
numbers and assuming the baseline epoetin dose would have remained stable over 12 
months, the median 12 month cost savings associated with darbepoetin was estimated at 
$212 000. The authors state that the cost savings would have likely been higher if they 
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had been converting from IV epoetin as the IV route is associated with one-third higher 
epoetin dose requirements. 
Roger et al published a study out of Australia in 2004 in which 60 hemodialysis patients 
were followed after switching from SC epoetin alfa to once weekly darbepoetin using a 
200:1 ratio to review the dose requirements and cost of switching.27 In phase 1 data was 
collected for 3 months before the switch and 3 months after the switch. In the second 
phase all patients were switched to double the darbepoetin dose every 2 weeks and were 
followed for 3 months. A protocol was used to adjust the dose ofESAs to maintain target 
Hb levels of 120-130g/L. An attempt to ensure adequate iron was made by aiming for a 
ferritin level between 300-600!-lg/L by administering IV iron weekly. Hemoglobin and 
ferritin remained within target during phase 1 but darbepoetin doses fe ll from 50.8!-lg to 
42.3 11g by the third month and the dose conversion ratio increased to 275.9:1. In phase 2, 
Hb was not maintained and doses had to be increased from 44.9!-lg to 47.5!-lg per week. 
They concluded that darbepoetin cost less per patient per year but the cost advantage is 
not as great when administered every two weeks to all patients. 
Martinez et al conducted a single-arm, multicenter trial in Spain which assessed the 
maintenance ofHb concentrations between 10-1 3g/dL in 826 dialysis patients (94% 
hemodialysis, 6% peritoneal dialysis) after switching from epoetin to darbepoetin.4 1 The 
study was published in 2003 and included both IV and SC administration of both epoetin 
and darbepoetin. Subjects were switched to darbepoetin using a 200:1 ratio and were 
followed for 24 weeks - a 20 week titration period followed by a 4 week evaluation 
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period. The study was completed by 86.8% of subjects and they found no significant 
change in Hb with a mean reduction of9.8% in the darbepoetin IV dose and 4.7% in the 
darbepoetin SC dose. 
Locatelli et al conducted a multi centre study in 19 European centres which was published 
in 2003.36 Three hundred forty one dialysis patients (329 hemodialysis, 14 peritoneal 
dialysis) on IV or SC epoetin alfa or beta were switched to IV or SC (maintaining same 
route) darbepoetin using a 200:1 ratio. There were 76 subjects receiving IV and 267 
receiving SC administration. Darbepoetin doses were adjusted to maintain each patient's 
hemoglobin within a target range of -1.0 to + 1.5g/dL of the mean baseline hemoglobin 
and between 10-13 g/dL throughout the study period. A dose protocol was used in which 
the dose was increased or decreased stepwise if the Hb was out of range for two 
consecutive assessments. Iron was administered intravenously as per individual unit 
policy to maintain serum ferritin above lOO!J.g/L. The primary outcome was the change in 
Hb from baseline to weeks 21-24 post conversion and the secondary outcome was the 
dose and frequency of darbepoetin administered. They found no difference in mean 
change in Hb. There was a significant decrease of 15% in the mean weekly IV 
darbepoetin dose from baseline to the evaluation period (25.2 IJ.g to 21.5 IJ.g) and the SC 
dosing requirement increased slightly from 20.8 IJ.g to 22.7 IJ.g weekly. They determined 
that the increase SC requirement seen was due to patients being sub-optimally managed 
on SC epoetin before the switch. 
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Martin-Holohan published a small pilot study of 14 hemodialysis patients in the United 
States in which hemodialysis patients were switched from SC epoetin alfa to SC 
darbepoetin.33 Subjects were switched using the manufacturer's conversion chart and 
were followed for 4 months to evaluate efficacy as measured by Hb levels and cost. Dose 
adjustments were made to maintain Hb levels between 11 0-120g/L, if Hb was below 
target the dose was increased by 50% and if above target the dose was decreased by 25%. 
Of the 12 patients who completed the study, 4 were not within Hb range before the switch 
and all of these required dose increases. In the other 8, half required one or more dose 
increases to maintain target. The cost analysis revealed that darbepoetin cost more but the 
difference was not statistically significant. This study was very small and not well 
designed in that one third of the patients were not at target at the time of switch. The 
dosing protocol with 50% increases was also unusual in that most dosing protocols use 
10-25% dose changes. The authors claim that they demonstrated that the manufacturer's 
conversion table resulted in insufficient darbepoetin doses, but it would be difficult to 
make any firm conclusions from this study. 
The nine prospective switch studies are summarized in Table 3. While none of these 
studies were ideally designed to answer the research question, four demonstrated a dose 
conversion ratio ( epoetin:darbepoetin) which was greater than 200:1 , four found 
decreased doses and lower cost with darbepoetin compared to epoetin and one found 
darbepoetin cost more than epoetin but the result was not statistically significant. 
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Table 3 : Prospective Switch Studies 
Subjects ESA Targets (l-I b, Fe) Outcomes Results 
Follow-up 
Hirai l-ID IV epoetin a to l-Ib I 00-1 20g/L Change in l-Ib and - Dose conversion ratio 
Japan, 2009-20 I 0 n= I04 IV darbepoetin TSAT>20% Darbcpoetin dose at 24 weeks 1:350.5 
Ferritin > 1 OOng/mL - Dose conversion ratio 
at 52 weeks I :286.6 
24 weeks and 52 
weeks 
Nakagawa HD epoetin a to l-I b 10-1 I g/dL Cost effectiveness - epoetin cost 
Japan, 2007 n=26 darbepoetin (cost per I g/dL Hb ¥31 09/1 g/dL of 
(letter to the ( route not Compared 2 four week per patient) l-Ib/patient 
editor) specified) periods - darbepoctin cost 
¥2 149/lg/dL of 
Hb/patient 
- savings of34% with 
darbepoetin 
Bock HD IV or SC epoetin Hb wi thin I g/dL of I 0 -change of - mean final dose 
Switzerland, 2007 n= l32 a or p to baseline (baseline darbepoetin dose conversion ratio I :336 
IV darbepoetin 10.8-13g/dL) - curvilinear relationship 
TSAT>20% 2°-change in mean between baseline 
Ferri ti n> I OO~tg/L Hb and safety epoet in dose and 
variables darbepoetin dose 
24 weeks 
lcardi l-ID IV epoetin a to Hb I 0.5-12.5g/dL Dose conversion - at month 7 ratio 
Italy, 2007 n=25 IV darbepoeti n Ferritin > I OOng/mL ratio 256. 1: I 
TSAT>20% - at month 12 ratio 
336.8: I 
12 months 
Shalansky HD SC epoetin a to Hb 120-1 35g/L I 0 -efticacy of - no significant 
Canada, 2005 n=95 IV darbcpocti n TSAT 20-50% darbcpoetin difference in l-Ib 
Ferritin I 00-800~tg/L compared to - median 12 month cost 
epoetin savings 
18 months $21 2 000 with 
2°-cvaluatc darbepoet in 
recommended - suggest converting 
conversion epoetin 7000units 
guidel ines, assess weekly or less using 
cost 200: I & greater than 
7000 units using 300: I 
Roger l-ID SC epoetin a to Hb 120-1 30g/L Dose requ irements - darbepoetin doses fell 
Australia,2004 n=60 IV darbepoetin Ferritin 300-600~tg/L and cost of and dose conversion 
switching ratio rose to 275.9: I 
6 months 
Martinez Caste lao HD(94%) & IV and SC Hb I 0-1 3g/dL Maintenance of - no change in Hb 
Spain, 2003 PO cpoetin to Hb and dose - 9.8% reduction in IV 
n=826 IV and SC 24 weeks required darbepoetin dose 
darbepoetin - 4.7% reduction in SC 
darbepoetin dose 
Locatell i HD&PD IV or SC epoctin l-Ib 10- 13g/dL I 0 - change in Hb - No change in Hb 
Italy, 2003 n=34 1 a or f3 to Ferritin> I OO~tg/L 2°-dose and - Decrease of 15% in 
Darbepoetin frequency of mean IV darbepoetin 
24 weeks darbepoetin dose from baseline 
- Small increase in SC 
darbepoetin dose 
required 
Martin-Holohan l-I D SC epoetin a to Hb 110-120g/L l-Ib and cost - 411 2 required dose 
US, 2004 n= 12 SC darbepoetin increases to meet target 
4 months Hb 
- Cost analysis: 
darbepoetin cost more 
but not statistically 
signi ficant 
HD=hcmodJalysJs, PD=pentoncal dJalys1s 
26 
2.4 Retrospective Switch Studies 
Sharma eta! conducted a retrospective observational cohort study in the United States 
from 2004-2005 with the goal of determining a robust empirical method to assess the 
dose conversion ratio between epoetin and darbepoetin? 8 Data was collected from the 
charts of hemodialysis patients from 25 hospital-based units who were switched from IV 
epoetin alfa to IV darbepoetin alfa. Twenty six randomly selected charts were chosen 
from each centre to provide data from 337 patients. Two analysis time frames were 
chosen of 8 weeks each - weeks 2-9 before conversion to darbepoetin and weeks 21-28 
after conversion, with 20 weeks in between to prevent carryover effects. Mean 
maintenance dose conversion ratios were calculated by two methods, one regression-
based (ordinary least squares) and the other ratio-based (arithmetic mean). Hemoglobin 
levels were comparable in both time frames. The regression based method provided a 
dose conversion ratio of 320:1 and the ratio-based method 350:1 , with sensitivity analyses 
yielding ratios from 311-333:1. The paper did not discuss if dosing protocols were in 
place in the centers under study for ESA or iron. 
Agrawal examined a retrospective cohort of 98 hemodialysis patients in the United States 
in a single centre who were switched from IV epoetin alfa to IV darbepoetin between 
2005 and 2006 using the manufacturer's conversion chart as pm1 of a therapeutic 
interchange program.42 The goal was to compare the effectiveness of the two ESAs by 
comparing mean Hb and variability. Data was collected for 8 months before the switch 
while still on epoetin, during the four month titration phase after the switch to darbepoetin 
and then for nine subsequent months. ESA doses were adjusted monthly to maintain the 
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individual's Hb between -1.0 and +1.5 g/dL oftheir baseline values with an overall target 
Hb of ll -1 3g/dL. lftwo consecutive assessments yielded Hb outside the target range, 
then doses were changed by 25%. Intravenous iron was used to maintain ferritin above 
200ng/mL and TSA T above 20%. The mean Hb levels, the proportion of patients able to 
achieve target Hb, and the Hb variability were not different between the two groups. The 
median dose of darbepoetin required to maintain Hb targets in the final 9 month phase 
increased significantly compared with baseline demonstrating a dose conversion ratio of 
190.8:1. 
Raymond et al performed a retrospective chart review of a switch from epoetin alfa to 
darbepoetin in hemodialysis, peritoneal dialysis and chronic kidney disease patients 
between 2003 and 2005 to determine dose conversion ratios.29 In 2004 in Manitoba, a 
policy change brought about this switch in ESAs based on a pilot study that 
demonstrated a dose conversion ratio>200: 1. Patients on both IV and SC epoetin were 
switched to the same route darbepoetin using the manufacturer's recommendations. 
Darbepoetin doses were titrated to a target Hb of 11 0-120g/L and iron was administered 
to maintain ferritin of 1 00-800ng/L and TSA T 20-50%. The study compared 857 patients 
on darbepoetin in 2005 (June to August) with 746 patients on epoetin in 2003-2004 (3 
months of data). The mean dose conversion ratios for IV administration in hemodialysis 
patients was 244:1 , for SC administration in peritoneal dialysis patients was 222:1 and for 
SC administration in chronic kidney disease patients was 219:1. 
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Biggar eta! conducted a retrospective cohort study of 90 hemodialysis patients as a 
quality control initiative to describe dose conversion ratios after a dialysis centre in 
Gennany underwent a switch from darbepoetin alfa to epoetin beta using a 200:1 ratio.30 
Dosing of ESA followed the "usual clinical routine" to maintain Hb targets of 11-12g/dL 
and iron status was maintained with intravenous iron to keep TSAT between 20-30%. The 
study collected data from 12 weeks before the switch and 16 weeks after the switch to 
analyze ESA dose and Hb level. After the switch to epoetin the mean Hb level decreased 
significantly from 11.4g/dL to 11.1 g/dL. The mean ESA dose required increased by 13% 
in the overall evaluation period. In the last four weeks the dose increased by 17%, 
suggesting a conversion ratio of >233:1. 
Brophy et al in the United States conducted a retrospective chart review following a 
therapeutic interchange program which switched all hospitalized hemodialysis patients 
from epoetin alfa to darbepoetin.35 They compared drug expenditures over a fiscal quarter 
in 2003 in 86 patients before the switch with historical comparator data from 56 patients 
in 2002. Data was also collected on patient demographics, drug utilization, and change in 
Hb for comparison purposes. The route of administration of the ESAs was not specified 
in the paper. There was no dosing protocol in place for epoetin but there was for 
darbepoetin after the switch. Patient demographics were similar between groups. Nearly 
all ofthe patients evaluated in the epoetin group were on drug, as no dosing protocol was 
in place. Comparatively, there was significantly less drug used in the darbepoetin group, 
only one-third of the patients received darbepoetin. The economic analysis demonstrated 
cost savings and reduced drug utilization with nearly $10 000 saved in the first quarter, 
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however this could be explained by the dosing protocol being implemented and not 
necessarily by the choice of ESA. Although it is worth noting that the cost per patient 
treated was lower with darbepoetin than epoetin. This study was in hospitalized patients 
only so it has limited generalizability. 
Sterner, in a letter to the editor, describes a retrospective analysis of a switch from SC 
epoetin beta to IV or SC darbepoetin in 155 hemodialysis patients in Sweden.31 Data was 
collected for an 8 month period after the switch and Hb levels and ESA doses were 
evaluated. It is not clear if a dosing protocol was used, but it is stated that iron 
administration was kept at an optimal level. The mean Hb at the start was 120g/L and it 
was 119g/L after 8 months. The mean epoetin beta weekly dose was 10 730 units and the 
mean weekly darbepoetin dose was 48 .1!-lg giving a mean conversion ratio of 257 :1. 
The retrospective switch studies are summarized in Table 4. Of the six studies reviewed, 
four found the dose conversion ratio (epoetin:darbepoetin) to be greater than 200:1, one 
found the dose conversion ratio to be less than 200:1 and one found cost savings and 
reduced drug utilization with darbepoetin compared to epoetin. Again, these studies were 
not designed to specifically answer the research question of interest and would also have 
the added inherent biases and limitations of retrospective studies. 
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Table 4: Retrospective Switch Studies 
Subjects ESA Targets (Hb, Fe) Outcomes Results 
Follow-up 
Sharma l-ID IV epoetin a to Not reported To determine dose - 320: I (regress ion based 
US, 2010 n=337 IV darbepoetin conversion ratios method) 
8 weeks before and 8 - 350: I (ratio based 
weeks after method) 
Agrawal HD IV epoetin a to l-Ib II 0-1 30g/L To determine dose - 190.8: I 
US, 2009 n=98 IV darbepoetin Ferritin>200pg/L conversion ratio 
TSAT>20% 
8 months before, 4 
months titration, 9 
months evaluation 
Raymond HD, PO, IV or SC l-Ib 11 0- 120g/L To determine dose - HD: 244: I (IV) 
Canada, 2008 CKD epoetin a to Ferritin I 00-800ng/L conversion ratios - PO 222: I (SC) 
n= 1603 IV or SC TSAT 20-50% - CKD: 219: I (SC) 
darbepoetin 
3 months before and 3 
months after 
Biggar HD IV darbepoetin l-I b 11 0-1 20g/L ESA dose and l-Ib - Mean epoetin dose 
Germany, n=90 to TSAT 20-30% increased by 13% 
2008 IV epoetin ~ - Suggest conversion ratio 
12 weeks before and of >233: I 
16 weeks after - 1-1 b decreased 
significantly after switch 
Brophy HD- Epoetin al fa to Not reported Drug uti lization and - Resulted in cost savings 
US, 2005 hospital ized darbepoetin cost, change in l-Ib and reduced drug 
n= 142 (route not 3 months before and 3 from admission to utilization 
reported) months after discharge - The average cost per 
patient treated was lower 
with darbepoetin than 
epoetin 
- No change in l-Ib 
Sterner HD SC epoetin ~ to Not reported Hb and ESA dose - l-Ib stable 
Sweden, 2008 n= 155 IV or SC - Mean dose conversion 
(letter to the darbepoetin 8 months after switch ratio was 257: I 
editor) 
HD=hemodmlySJS, PD=pentoneal d1al ys1s, CKD=Chromc K1dney D1seasc 
2.5 Cross-Sectional Studies 
Courtney published a cross-sectional analysis of ESA prescribing from four dialysis 
centres in Northern Ireland in 2006.43 The four units shared the same guidelines for ESA 
and iron dosing, although the choice of agent and route of administration were at the 
discretion of the individual nephrologist. Data was collected on 403 patients including 
184 on epoetin beta and 219 on darbepoetin to compare mean Hb between groups and 
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ESA dosing. Over a selected one week period the ESA, dose, route of administration, iron 
dose, Hb, ferritin, TSA T, and PTH were collected. Patients could be on either SC or IV 
ESA. The mean Hb was comparable between groups. They determined the dose 
conversion ratios to be 176:1 between SC epoetin and SC darbepoetin, 200:1 between IV 
epoetin and TV darbepoetin and 1 73 : 1 between SC epoetin and IV darbepoetin. Based on 
this, SC epoetin beta was the most cost effective ESA in this population. 
2.6 Economic Studies 
Churchill, in 2007, published a prospective observational study of non-acquisition costs 
associated with ESA administration with the goal of determining how much costs could 
be decreased with the less frequent dosing of darbepoetin and less frequent ferritin 
monitoring.44 The costs associated with anemia management were evaluated in 450 
hemodialysis patients in Hamilton in 2001 who were receiving SC epoetin alfa with a 
target Hb of 110-1 20g/L and IV iron to maintain ferritin above lOOj...lg/L and TSAT above 
20%. These data were used to estimate costs in 2005 using an inflation factor. Time-and-
motion teclmique was used to determine nursing time for preparation and administration. 
Fixed anemia costs included inventory control, monitoring, blood sampling and lab 
analysis. Variable costs were those that varied with dosing frequency. A dose conversion 
ratio of 200:1 and dosing every 2 weeks was assumed for darbepoetin. The analysis found 
that less frequent iron monitoring and less frequent ESA dosing would decrease costs by 
$678.40 and $199.38 per patient year respectively. More specifically, in changing from 
three times weekly epoetin to once weekly darbepoetin $308.11 per year per patient 
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would be saved and from twice weekly epoetin to once weekly darbepoetin $154.05 per 
year per patient. It was noted that the change in iron monitoring would represent a 
monetary cost reduction whereas the decreased dosing represents nursing time which 
would not likely lead to a decrease in nursing staff. As is standard in economic analyses, 
the time represents a potential cost savings in the long run assuming that resources can be 
deployed differently and more efficiently. 
Morreale conducted a cost-minimization analysis in the United States in 2003 to compare 
epoetin alfa and darbepoetin.45 The goal was to calculate a cost ratio based on the 
available clinical trials in both chronic kidney disease and oncology. As comparative head 
to head trials were not available, they claimed that clinical endpoints in the available 
studies were similar and used them to conduct the analysis from a provider's perspective. 
Using data from the selected studies they calculated cost comparison ratios of 
darbepoetin:epoetin in the different patient populations and concluded that epoetin alfa is 
a better pharmacoeconomic value overall. In dialysis the cost ratio was 1.5 and 2 in the 
two studies used . Specifically in hemodialysis a cost ratio of 1.4-3 was found in the one 
study used. This economic analysis was based on a limited number of studies and costs 
were determined based on available vial sizes at the time. The results would be of 
questionable relevance currently. 
Kruep et al conducted a cost-minimization analysis to compare darbepoetin and epoetin 
alfa in the hospital wide setting.34 It was an observational retrospective review of use for 
all indications in the United States in 2003. They considered total costs including drug 
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product costs and administration costs. There were 429 records of epoetin and 80 records 
of darbepoetin and data was collected to determine the dose conversion ratio. The overall 
dose conversion ratio based on median daily dose of each drug was found to be 245: 1, the 
authors concluded that there was no cost difference between the two as they determined 
the breakeven point to be 239:1. Sensitivity analyses were conducted and found that a 
cost benefit would only be realized when the dose conversion ratio exceeded 257:1. This 
study may have limited applicability as it was in the hospital setting only, it included ESA 
use for all indications and there were many assumptions made about drug vial size (i.e. 
for a 5000 unit dose, a 1 0 000 unit vial was assumed to be used). 
2.7 Systematic Reviews 
Cremieux published a systematic review based on comparative switch and non-switch 
studies in CKD published between 2000 and 2005.46 A dose ratio from epoetin alfa to 
darbepoetin was calculated for each study and the results were stratified by study 
characteristics. Multivariate regression analysis was used to control for differences in 
study design and a dose conversion ratio for Canada was estimated. They identified 21 
studies involving 16 378 patients from the United States, Canada, Europe and Australia. 
There were 15 switch studies, 4 randomized controlled trials and 2 parallel group studies 
with an average treatment period of 26.4 weeks. Univariate analysis of the dose ratios 
gave a mean dose ratio of217: 1 and multivariate analysis demonstrated that the study 
design and the geographical area affected the results. Based on the multivariate analysis 
the dose conversion ratio for Canada was determined to be 169: 1, meaning epoetin alfa 
would cost 11 -18% less than darbepoetin. There was much variation in design amongst 
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the small nwnber of studies used with a lack of uniformity in the outcomes measured and 
a likely variation in iron status (this was not managed in the analysis as most did not 
report infonnation on iron supplementation). As most were switch studies, they would 
have the bias inherent in this type of study (discussed in Summary). Also there was 
insufficient data to conduct a systematic analysis of the change in dose conversion ratio 
over time and there is evidence to suggest that the ratio changes over time as the 
darbepoetin dose stabilizes. 
Duh conducted a systematic review in 2008 in which the pharmacoeconomic evidence on 
the comparative cost effectiveness of epoetin alfa, epoetin beta and darbepoetin in CKD, 
oncology and other disease areas was reviewed. 14 Studies published between 2000 and 
2007 were used and in the dialysis population there were 4 studies identified. In the end 
the authors state that it is difficult to draw conclusions about the relative cost 
effectiveness in this population from the literature that is available, even though a number 
of studies suggest an advantage for epoetin alfa. It is noted that cost differences exist 
between countries making comparisons difficult - in Canadian studies, hospital contract 
prices are often used whereas in US studies wholesale costs are more common. The 
majority of the studies reviewed in this paper are from the oncology literature. 
A systematic review and economic evaluation of ESAs in CKD was published by 
CADTH (Canadian Agency for Drugs and Technology in Health) in 2008.37 This review 
was done primarily to address the uncertainty about using ESAs to target higher Hb 
levels. Randomized controlled trials in anemic adults with CKD managed with epoetin, 
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darbepoetin or without ESA were included to conduct a cost-utility analysis from the 
perspective of the Canadian public health care system using a lifetime horizon. Base case 
analysis and probabilistic sensitivity analyses were done. The results showed that 
intermediate and low Hb targets are optimal and that a Hb target of 11 Og/L produces the 
largest number of quality adjusted life years (QAL Ys) at an additional cost per patient 
lifetime. However, this was based on the assumption that the intermediate target will 
improve quality of life compared to the low Hb target and this is unproven. In dialysis 
specifically, they found costs could be reduced if SC epoetin or darbepoetin (IV or SC) 
were used instead of IV epoetin. The authors state that head-to-head comparisons of 
epoetin and darbepoetin should be undertaken because even small differences in potency 
per unit cost of ESA can translate into large difference in total costs to the Canadian 
public health care system. 
2.8 Summary 
The one randomized controlled trial with just intravenous ESA administration did not 
have dose or cost as the primary outcome. The other two which did evaluate dose 
involved subcutaneous administration. The route of administration is very important as 
ESAs in hemodialysis patients are almost exclusively administered by the intravenous 
route. 
The term "switch study" is being used for studies that examine outcomes before and after 
conversion of a whole population from one ESA to the other (also referred to as historic 
control or pre- and post- study). In such studies it is difficult to interpret and generalize 
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results due to the absence of a control group and the tendency for ESA requirements to 
change in hemodialysis populations over time as guidelines and practices evolve. 
Particularly in the retrospective switch studies, the cohorts compared were often different 
groups of patients over different time periods, this alone could account for a difference in 
ESA requirement. 
Most of the prospective switch studies did not include a pre-switch component in which 
the epoetin doses were stabilized. Without this, there is the potential that epoetin dosing 
before the switch may have been sub-optimal or patients may not have been iron replete. 
Once the switch to darbepoetin occurred many of the studies describe set dosing protocols 
or iron and hemoglobin targets. Any differences found could have been in part due to 
more diligent dosing post switch. Of the prospective switch studies, only two were in 
North America, several had a follow up period of less than 6 months and not all used 
standard, pre-defined dosing protocols. 
In the retrospective switch studies there is the added limitation of potential selection bias, 
several compared completely different groups of patients from different time periods, 
only two of the six evaluated longer than 6 months post-switch, most did not identify set 
protocols for dosing ESA and iron, and many did not report if subjects were iron replete. 
Some of the authors of these papers suggest that retrospective cohort studies may be more 
generalizable and representative of the real-world dialysis population than a prospective 
study which excludes many patients for a variety of reasons. While generalizability may 
be limited in prospective studies and trials with inclusion criteria, the potential for bias in 
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the retrospective studies remains and would limit the conclusions and inferences that 
could be drawn from the results. 
The cross-sectional study examined a one week period only in four different centres in 
Ireland without standardized dosing protocols. It may have use in describing practice 
patterns in this region at a given time, but could not be relied upon to make conclusions 
about cost differences ofESAs for all dialysis patients. 
Of the three economic analyses, one focused on non-acquisition costs only, one combined 
CKD and oncology trials and the third was just in the inpatient hospital setting. These 
were based on a limited number of studies, mostly observational switch studies with a 
variety of designs and a number of limitations. The most applicable systematic review to 
address the question was done in Canada but even here the authors concluded that more 
head-to-head comparisons are needed to fully evaluate any cost differences between 
epoetin and darbepoetin. 
None of the studies identified met all the desired characteristics to address the question of 
a cost advantage for intravenous epoetin or darbepoetin in the management of CKD 
anemia in hemodialysis patients. Overall, the results of the various study types 
demonstrated a trend towards lower dose requirements with darbepoetin and higher dose 
conversion ratios than 200:1 . 
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Chapter 3 Research Design 
3.1 Overview 
This study was an open label, unblinded, randomized controlled trial of intravenous 
darbepoetin alfa (Aranesp®) versus epoetin alfa (Eprex®). Eligible subjects were 
prevalent and incident hemodialysis patients who were unlikely to recover renal function, 
required ESA therapy, did not have a known cause fo r anemia other than chronic kidney 
disease, and did not meet the criteria for ESA resistance. Subjects were enrolled over a 
minimum six week run-in period to ensure that the hemoglobin was stable within the 
target range. The active study period then continued for a subsequent 12 months. ESA 
and iron were dosed according to an algorithm designed to maintain hemoglobin within 
the currently recommended target range of 1 00-120g/L. Subjects could be recruited from 
any of the following dialysis units: Health Sciences Center Dialysis Unit (St. John's, L), 
Waterford Hospital Dialysis Unit (St. John's, L) or Carbonear Dialysis nit (Satellite 
Unit, Carbonear, NL). 
3.2 Outcomes 
The primary outcome was the cost per patient of ESA required to maintain hemoglobin in 
the target range over 12 months. Secondary outcomes included time to dose stabilization, 
number of dose changes, the dose conversion ratio, iron dose and cost and deviation from 
target ranges for hemoglobin and iron indices. 
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3.3 Sample Size Calculation 
Because the primary outcome was cost, any of several statistical approaches to sample 
size calculation were appropriate. An important assumption of this study was that the 
clinical effectiveness and hence the clinical utility of both treatments is identical. 
Because of this, a cost minimization analysis was done and more complicated approaches 
to sample size calculation for economic analyses that allow the cost and the clinical 
benefit of each treatment to vary were not required. 
The primary analysis was a comparison of cost per patient per year between groups. An 
audit of the dialysis unit in St. John's determined that the mean direct drug cost per 
patient over 12 months was approximately $7,000 with a standard deviation of$1 ,500 
(not inclusive of pharmacy and nursing costs). Based on these figures, the total number 
of patients required to detect a difference of $800 per patient with 2 - sided a=0.05 and 
power (1-~)=0.80 was ll 2, or 56 per group. 
3.4 Subjects 
The eligible study population included patients receiving or initiating hemodialysis who 
met the following inclusion criteria: 
1. Age ~ 19 years 
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2. End-stage chronic kidney disease necessitating maintenance hemodialysis therapy 
that, in the opinion of the responsible physician, was permanent and unlikely to 
resolve with or without treatment 
3. Receiving hemodialysis two or more time weekly 
4. Anemia due to renal failure requiring ESA therapy OR a Hb< 1 OOg/L in the 
absence of other causes of anemia 
5. If female, must be using an approved method of contraception (barrier, hormonal 
contraceptives) or judged unable to become pregnant 
6. Able to understand and sign the informed consent document 
Patients who met any of the following exclusion criteria were not eligible for study 
participation: 
1. Renal failure that, in the opinion of the responsible physician, was acute and likely 
to resolve 
2. Being treated with, or definite plans to change to, peritoneal dialysis (PD), home 
hemodialysis, home nocturnal dialysis or planned transplant from a living donor 
3. Presence of a medical condition other than renal failure expected to limit the 
patient's lifespan to less than six months from the time of assessment 
4. Current diagnosis of a hematologic condition other than erythropoietin and I or 
iron deficiency that may cause anemia 
5. Current use of medications known to cause anemia 
6. Use of any investigational drug or androgens within 90 days of screening 
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7. Documented significant bleeding, including gastrointestinal bleeding, pulmonary 
hemotThage, gross hematuria or mennorhagia, that was either untreated or 
unresolved, within 30 days of screening 
8. Red blood cell transfusion(s) within 30 days of screening 
9. Documented or suspected pure red cell aplasia (PRCA) 
10. CmTent iron deficiency (i.e. ferritin < 2001-1giL and I or transferrin saturation < 
20%). Patients were eligible for enrollment if this was subsequently corrected 
using intravenous iron therapy 
11. Documented allergy or intolerance to intravenous sodium fen·ic gluconate 
(Fenlecit®) 
12. Known or probable ESA resistance. For the purpose of this study, resistance was 
defined as: 
a. a cunent requirement for Eprex ® ::::: 250 unjts/kg/week 
b. documented current vitamin B 12 and I or folate deficiency 
c. the presence of an untreated or unresolved malignancy, other than basal 
cell carcinoma 
d. current iPTH (parathyroid hormone) > 1 OOOngiL 
e. the presence of an active infection (i.e. any infection that was currently 
being treated with antibiotics), any diagnosed infection that was not 
treated with antibiotics but have been awaiting therapy by other means 
(i.e. amputation of a gangrenous limb), or a history of osteomyelitis in the 
preceding 3 months even if antibiotic therapy has been completed 
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13. Uncontrolled hypertension (as determined by the attending nephrologist) 
14. Inability to comprehend or unwillingness to sign the informed consent document 
15. An intention to move away from the current region in the near future 
necessitating a change of dialysis center 
3.5 Randomization 
Eligible patients who agreed to participate in the study and signed the informed consent 
document were randomized prior to the run-in period using a variable, block 
randomization procedure. Before any subjects were enrolled, a random number sequence 
was used to determine the order of the variable blocks of 4, 6 or 8 and the sequence of 
assignment within each block. One of the investigators filled and numbered the opaque 
envelopes and the sequence was sealed and filed until the end of enrollment to ensure that 
the investigators were blinded to the order of assignment. As each subject was enrolled, a 
sealed envelope was sequentially opened by an investigator to assign the study subjects to 
one of two groups: 
Group 1: Continued treatment with epoetin (Eprex ®)to maintain Hb 100-120 g/L 
Group 2: Switch to darbepoetin (Aranesp ®)to maintain Hb 100-120 g/L 
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3.6 Study Protocol 
3.6.1 Run-In Period 
The purpose of the run-in period was to ensure that subjects assigned to epoetin had a Hb 
that was stable in the 1 00-120g/L range, and to allow ESA conversion and dose titration 
of subjects in the darbepoetin group such that their Hb remained within an identical target 
range. Data from the run-in period was not included in the final analysis of drug cost, but 
Hb stability and time to target Hb were examined as secondary outcomes. 
For both groups the run-in period was a minimum of six weeks. Hemoglobin levels were 
determined at mandatory two week intervals during the run-in phase. If an enrolled 
subject's hemoglobin was within the range of 100-120 g/L for three consecutive two-
weekly measurements, that subject was considered stable and entered the active study 
phase. If a subject's hemoglobin deviated from the target range, drug dose adjustments 
were made according to the study algorithms (Appendices A and B) and the run-in period 
was extended until the stability criterion was met. 
3 .6.2 Intervention 
All changes in ESA and iron therapy were made in accordance with the specified study 
algorithms (Appendices A and B). Once a subject was enrolled in the study, all ESA and 
iron prescription adjustments were made by the study investigators. Hb was measured at 
baseline and every 2 weeks during the run-in phase. The second Hb measurement during 
the run in phase was used to ensure that Hb remained in a safe and acceptable range. If 
the Hb measure exceeded specified safety criteria the treating physician was alerted to 
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manage as they deemed appropriate. Such management could have included, but was not 
limited to, changes in the ESA dose, blood transfusion, further investigations or 
diagnostic tests. During the active study phase, Hb was measured monthly and dose 
changes were made as per the study algorithms. 
3.6.3 Epoetin (Eprex®) Dosing 
Patients who were emolled and randomized to the epoetin group remained on their 
cun-ent dose and frequency for the first two week interval. After the first Hb measurement 
the study algorithm was used to guide anemia management (Appendix A). The first Hb 
measurement (at two weeks) was reviewed by the investigators to determine whether 
changes in epoetin were required to ensure patient safety or whether further investigations 
were required (see above). The second Hb measurement (at 4 weeks) was used to make 
changes in epoetin dose, if required, to maintain the patient's Hb in the target range. This 
cycle repeated itself throughout the run-in phase. During the active study phase, the Hb 
measurement was reviewed once monthly by investigators to determine if changes in 
epoetin dose were required to maintain the patient's Hb in the target range. This 
continued until the study tenninated or the patient was withdrawn from the study. 
If a subject required a dose of epoetin > 30 000 units weekly, the dose was not escalated 
any higher. Such a patient would likely meet the criteria for study withdrawal (see 3.9). 
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All epoetin was administered intravenously during dialysis through a hemodialysis 
machine port using a manufacturer-provided pre-filled syringe. This was the standard 
practice in the dialysis units. 
3.6.4 Darbepoetin (Aranesp®) Dosing 
In patients who were randomized to the darbepoetin group, their current ESA was 
discontinued at the end of the week preceding entry into the study. These patients were 
switched to darbepoetin on the date that they would normally have received their next 
dose ofESA. Switching patients to darbepoetin was done using the conversion ratio of 
200 units of epoetin to 1 )lg of darbepoetin as used per week, rounded up or down to the 
nearest available pre-filled syringe dose available from the manufacturer. All darbepoetin 
was administered intravenously during dialysis through a hemodialysis machine port. 
As in the comparator group, after the first Hb measurement the study algorithm was used 
to guide anemia management (Appendix A). The first Hb measurement (at two weeks) 
was reviewed by the investigators to determine whether changes in darbepoetin or other 
interventions were required. Because this group was undergoing a switch in their 
therapy, the potential existed for a significant change in Hb in either direction during the 
run-in phase. The protocol allowed the result of the first Hb measurement to be used to 
change the dose of darbepoetin if the subject's Hb fell out of range or if the investigator 
anticipated that this would occur without a change in dose. The second Hb measurement 
(at 4 weeks) was used to make changes in darbepoetin dose, if required, to maintain the 
patient's Hb in the target range. This cycle repeated itself throughout the run-in phase. 
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During the active study phase, the Hb measurement was reviewed once monthly by 
investigators to determine if changes in darbepoetin dose were required to maintain the 
patient's Hb in the target range. This continued until the study terminated or the patient 
was withdrawn from the study. 
If a subject required a dose of darbepoetin > 150!1g weekly, the dose was not escalated 
any higher. Such a patient would likely meet the criteria for study withdrawal (see 3.9). 
3.6.5 Iron Dosing 
Iron supplementation is an integral component of anemia management in hemodialysis 
patients. The current practice of the participating dialysis units was to administer 
intravenous iron to patients as required to maintain serum iron indices within 
recommended ranges. There are three iron products available for use in Canada: non 
dextran (Infufer®), Iron sucrose (Venofer®), and Sodium Ferric Gluconate (Ferrlecit®). 
All three formulations are used in the participating dialysis units and are considered 
equally efficacious. 
Patients enrolled in this study received only one formulation of iron, Sodium Ferric 
Gluconate (Ferrlecit®), as it is moderate in cost and the risk of anaphylactoid reactions is 
significantly less than seen with iron dextran. The use of one iron product in all patients 
ensured a standard approach and eliminated a potential confounder. 
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Intravenous iron was prescribed if indicated according to the study algorithm (Appendix 
B) to maintain serum ferritin in the range of200-800ng/mL and TSAT between 20-50%. 
As part of standard clinical practice, TSA Twas measured monthly and ferritin every 3 
months. The most recent values were used to determine study eligibility. After 
enrollment in the study, iron parameters continued to be measured at this frequency. 
3. 7 Data Collection and Storage 
Data was obtained from the Meditech® system and I or the subject's chart as it was 
available at baseline and every two weeks thereafter during the run-in and once monthly 
during the active phase. Data was entered directly into a statistical software database 
(SPSS®) using unique patient identifiers that were not traceable to individual subjects by 
anyone other than the study investigators. All data was secured and stored in locked areas 
inaccessible to non-study pers01mel. 
3.8 Analysis 
Analysis of the primary outcome was a comparison of the total ESA cost over 12 months 
per patient in each group. The cost used in the analysis was the drug acquisition cost only 
(manufacturer' s list price, Canadian dollars) . The agents are priced such that the cost is 
equivalent for the two at a 200:1 dosing ratio ( epoetin: darbepoetin). After determining 
that the distribution of the costs was not normal, medians and interquartile ranges were 
calculated and the medians were compared using the Mmm-Whitney U test. 
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Secondary analyses included: 
• A comparison of iron dose and cost over 12 months for each group 
• A comparison of the achieved targets of anemia management between the 
two groups including Hb, TSAT and Serum Ferritin 
• A comparison ofthe number of weeks and dose changes required to 
achieve dose stabilization in each group in the run-in phase 
• A comparison of the number of dose changes throughout the active phase 
• A calculation of the dose conversion ratio between epoetin and 
darbepoetin by comparing the epoetin dose prior to conversion with the 
darbepoetin dose at the point of dose stabilization and at the 3 and 6 month 
points of the active phase 
For the secondary analyses, when the distribution of the data was normal, results were 
reported as means ± standard deviation (SD) and the independent samples t-test was used 
to compare means. When the data was not normally distributed, results were reported as 
medians and interquartile range (IQR) and the nonparametric Mann-Whitney U test was 
used to compare medians. 
3.9 Withdrawals 
Patients who withdrew from the study prior to the active study phase were not included in 
the final analysis. Patients who withdrew from the study after this point were included in 
49 
the final intention to treat analysis, using all data that was available up until the point that 
the subject finished . 
If patients had required blood transfusions, they would not have been withdrawn from the 
study for this reason alone. The data from these patients would have been included in the 
final analysis, but the occurrence and frequency of transfusions would have been noted in 
the final results. In the circumstance that a subject previously requiring ESA no longer 
required it to stay in the target Hb range, that patient was not withdrawn from the study. 
At any point an individual patient may develop a condition that significantly alters their 
response to ESA or, at the extreme, makes the use ofESA futile or impractical. A patient 
who is diagnosed with a malignancy, for example, may undergo chemotherapy that will 
cause severe anemia. Withdrawals from the study protocol were permitted at the 
investigator's discretion for the following reasons: 
1. newly documented or suspected pure red cell aplasia (PRCA) 
2. a newly diagnosed hematologic condition other than erythropoietin and/or iron 
deficiency that may cause anemia and was not immediately remediable 
3. the initiation of drug therapy that was expected to cause anemia or significantly 
impact the patient's response to ESA, e.g. chemotherapy 
4. the diagnosis of significant bleeding, including gastrointestinal bleeding, 
pulmonary hemorrhage, gross hematuria or menorrhagia, that was either 
untreatable or not to be treated 
5. withdrawal ofrenal replacement therapy 
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6. clear evidence of ESA resistance, regardless of cause, such that the attending 
physician determined that it would be futile to further increase the dose of ESA 
3.10 Ethical Considerations 
Ethics approval was obtained for this study from the Health Research Ethics Authority 
(HREA, formerly the HIC - Human Investigation Committee) in July 2010, with 
subsequent renewals in 2011 and 2012. The study was also reviewed and approved by the 
Research Proposals Approval Committee (RPAC) ofEastern Health. 
An informed consent document (Appendix C) was developed as per the suggested 
template from the HREA, and was approved along with the protocol. A study investigator 
reviewed this document with each potential subject. Time was given to review the 
document at home and bring forward any questions. After signing each subject was 
provided with a copy. 
With respect to the choice of therapeutic agents, epoetin (Eprex®) and darbepoetin 
(Aranesp®) are competing products that are generally considered equally efficacious and 
have identical side effect profiles. Both drugs are given intravenously via dialysis 
machine ports with pre-filled syringes and are not associated with any discomfort or 
sensation during administration. The frequency of dosing did not affect the patients in 
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any way and the dialysis procedure was not prolonged or altered by administering one 
versus the other. 
Complimentary drug was not provided by either manufacturer for this study and usual 
retail prices were paid for both. Both drugs have identical cost coverage with the 
Newfoundland and Labrador Prescription Drug Program (NLPDP) and all private 
insurance programs in this province. Currently, a nephrologist may prescribe either drug 
at their own discretion. 
The only deviation from current clinical practice for subjects emolled in this study was 
one additional CBC (complete blood count) per month during the run-in period. This 
represented an additional 10 mL of blood for testing per month, which was taken from the 
dialysis machine lines prior to dialysis and did not require venipuncture. This degree of 
blood loss was minimal and Hb was monitored closely throughout the study. Subjects 
were not subjected to any additional procedures, tests, surveys, interviews, or physical 
examinations. 
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Chapter 4 Results 
4.1 Subjects 
Figure 1 presents the flow of subjects through the trial. Between September 20 10 and 
February 2012, 208 hemodialysis patients were screened for inclusion. Of these, 25 were 
not currently treated with an ESA and 98 met one of the exclusion criteria. The most 
common reasons for exclusion were an allergy or intolerance to Ferrlecit® (16), inability 
to comprehend and sign the consent document (20), or an intention to move to another 
centre (20). This left 85 eligible patients. The study investigator approached each eligi ble 
patient to explain the trial including the purpose and the implications for subjects. Each 
patient was provided with a copy of the consent document (Appendix C) to take away to 
read and consider at home. Within a week, the investigator met with the patient again to 
answer any questions and to complete the signing of the consent docw11ent if the 
individual had decided to participate. Of the 85 patients, 34 declined to participate and the 
reasons (if any) given were recorded and are outlined in Figure 1. Subsequently, 51 
patients consented to participate and were randomized. 
Of the 51 patients enrolled, 24 were randomized to the epoetin arm and 27 to the 
darbepoetin arm. Baseline characteristics are presented in Table 5. One subject in the 
darbepoetin arm was withdrawn from the study before the completion of the run-in phase 
due to the new diagnosis of a hematological condition. As dose stabilization did not 
occur, none of the data for this subject were included in the analysis. The final study 
groups consisted of24 subjects in the epoetin arm and 26 subjects in the darbepoetin arm. 
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In the active phase, 8 subjects did not complete the full 12 months of follow up, 5 from 
the darbepoetin arm and 3 from the epoetin arm. Four of the patients died (after 2, 6, 7, 
and 9 months), one switched to peritoneal dialysis (after 6 months), one moved away 
unexpectedly (after 8 months), and 2 received kidney transplants (after 5 and 7 months). 
All of the data from these subjects were included in the final analysis with the last 
available month's data carried forward to the end. 
Table 5: Demographics and Baseline Characteristics of Subjects 
Epoetin( n=24) Darbepoetin(n=26) 
Age (mean±SD) 59.8 ± 13 .3 61.0 ± 15.1 
Male 13 20 
Female 11 6 
Baseline epoetin dose 6083 ± 3450 6654 ± 4749 
(units weekly, mean±SD) 
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Figure 1: Patient Flow Diagram 
208 Patients Screened 
(Sept 20 l 0-Feb 20 12) 
\I 
85 Eligible 
\ 
123 Excluded: 
Planned PD, Home HD or Transplant=8 
Expected Lifespan<6months= l 
Hematological Condition=2 
Study Drug within 90 days=2 
Significant Bleeding with in 30 days= I 
Blood Transfusion with in 30 days= l 
Iron Deficiency=7 
Allergy or Intolerance to Sodium Ferric 
G luconate= 16 
Epoetin alfa dose2:250units/kg/week=3 
Malignancy=3 
PTH> lOOOng/L= ll 
Infect ion, Gangrenous Limb, Osteomyelitis 
last 3 months=3 
Inability to Comprehend/Sign Consent=20 
Intention to Move=20 
Not on ESA=25 
34 Declined: 
No Reason Provided=20 
Concerned about Transfus ion=2 
Concerned about Change in ESA=8 
Insurance Concerns=2 
Adverse Reaction to darbepoetin alfa in the 
past=2 
51 Consented and Randomized 
epoetin=24 
II 
3 incomplete: 
I death, I moved, I 
transplant 
I 
darbepoetin=26 
5 incomplete: 
3 deaths, I transplant, I 
PD 
I withdrawn: 
myelodysplasia 
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4.2 Primary Outcome - Total ESA Cost 
The histogram in Figure 2 demonstrates the distribution of the total ESA cost over the 
twelve month active phase. Skewness was 1.163 with a standard error of 0.337 and it does 
not meet the requirements for normality according to the Shapiro-Wilk test. When 
separated by study group, the distribution of total epoetin cost is normal (Figure 3), but 
darbepoetin continues to have a right skew (Figure 4). This necessitated the use of the 
nonparametric Mann-Whitney U test to compare groups as the independent t-test can only 
be used if the dependent variable is approximately normally distributed within each 
group. 
H i stogram 
.00 2000.00 4000.00 6000.00 8000.00 10000.00 uooo.oo 
Tot al ESA Cost 12 months 
Mean = 377 1. 10 
Std . D ev . = 2782.532 
N = ~0 
Figure 2: Distribution of Total ESA Cost over the 12 Month Active Study Phase 
(Epoetin and Darbepoetin Groups Combined) 
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Figure 4: Distribution of Total Darbepoetin Cost over the 12 Month Active Study 
Phase 
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As is demonstrated in the boxplot in Figure 5, there was a major outlier (subject 26) in the 
darbepoetin arm. By the end of the active phase, the dose had escalated in this subject to 
the maximum dose of 1 50~-tg weekly and in the months after study completion the 
definition of ESA resistance was met in this case. 
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Figure 5: Boxplot of Total Epoetin and Darbepoetin Cost over the 12 Month Active 
Study Phase Demonstrating Outliers 
To determine if this outlier was the cause for the skew in the darbepoetin data and if a 
case should be made to exclude this case, descriptive analysis was run with subject 26 
excluded. As can be seen from Figure 6, the histogram for darbepoetin remains skewed 
with a value reported of 1.82 and a standard error of 0.524. The data still does not meet 
the requirements for normality according to the Shapiro-Wilk test. As a result, it was 
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determined that subject 26 was not the sole reason for the distribution of the data in the 
darbepoetin arm and all data were used in the analysis. 
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Figure 6: Distribution of Total Darbepoetin Cost over the 12 Month Active Study 
Phase with Outlier Removed 
Results for the primary outcome and anemia targets are summarized in Table 6. The 
primary outcome was the total cost per patient ofESA required to maintain hemoglobin 
in the target range over 12 months. Total ESA cost was not normally distributed so results 
are expressed as median (interquartile range) and medians were compared using the 
Mann-Whitney U test. 
The median total cost for epoetin over 12 months was $4178.70($2416.37-5955.1 2) and 
for darbepoetin was $2302.92($11 77.86-42 18.93). The median cost of darbepoetin was 
$1875.78 less per year than epoetin and the difference was statistically significant 
(p=0.01 7). 
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Table 6: Comparison Between Epoetin and Darbepoetin Groups of Total ESA Cost 
and Anemia Targets During The 12 Month Active Study Phase 
Outcome Epoetin (n=24) Darbepoetin(n=26) p Value 
Total ESA Cost ($) 4178.70 2302.92 0.017a 
(median, IQR) (2416.37-5955.1 2) (1177.86-421 8.93) 
Hb (g/L) 108.00 109.75 0.336a 
(median, IQR) (1 06.00-112.71 ) (1 05.88-116.08) 
Ferritin (f.lg/L) 847.58 ± 272.88 726.29 ± 377. 13 0.202b 
(mean±SD) 
TSAT (%) 26.71 (22.46-32.33) 28.58 (23.90-33.75) 0.472 a 
(median, IQR) 
Iron Dose (mg,weekly) 40.36 (20.83-59.90) 41.67 (19.53-70.96) 0.992a 
(median, IQR) 
Total Iron Cost ($) 726.56 750.00 0.992a 
(median, IQR) (375.00-1 078.13) (351.56-1277.34) 
a b . Matm-Whitney U test mdependent samples t-test 
4.3 Anemia Targets 
As secondary outcomes, Hb, serum fe rritin, TSA T, iron dose and iron cost were 
compared between the two groups. Of these, Hb, TSAT, iron dose and iron cost were not 
normally distributed so the Mann-Whitney U test was used to compare medians. Serum 
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ferritin was normally distributed so the means were compared using the independent 
samples t-test. 
There were no statistically significant differences between the two groups in any of the 
anemia targets compared. The median hemoglobin over 12 months was 1 08.0g/L in the 
epoetin group and 109.75g/L in the darbepoetin group (p=0.336). Mean serum ferritin in 
the epoetin group was 847.581-lg/L and the darbepoetin group was 726.291-lg/L (p=0.202). 
The median TSA T in the epoetin group was 26.71% and in the darbepoetin group was 
28.58% (p=0.472). The median weekly iron (Ferrlecit®) doses were not different with the 
epoetin group receiving 40.36mg and the darbepoetin group 41 .67mg (p=0.992). Median 
total annual iron (Ferrlecit®) cost was $726.56 in the epoetin group and $750.0 in the 
darbepoetin group (p=0.992). 
As stated above, the mean hemoglobin over the total 12 month study period was not 
different in the two arms. It is also of interest to know how the hemoglobin varied over 
the study period in both groups, particularly with respect to the target range of 100-
120g/L. To examine this, the mean hemoglobin in each arm was determined for each two 
week period of the Run In Phase and for each month of the Active Phase. Figures 7 and 8 
show the two phases graphed separately and Figure 9 is for the entire study period. 
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Mean Hemoglobin Active Phase 
130 
..... 
Cia 125 
c 
:c 
0 
bl! 
0 
E 
Cll 
J: 
c 
l1l 
Cll 
~ 
120 
115 ,"1.._-Ll--f}'~f;J..... 
105 
100 
95 
1 2 3 4 5 6 7 8 9 10 11 12 
Month 
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During the Run-In Phase (Figure 7), the mean Hb in both groups remained within the 
target range, with one exception in the darbepoetin ann during week 8 when the mean 
was 12 l g/L. As can be seen in Figure 8, both groups remained within the target during 
the Active Phase with minimal variation. 
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Figure 9: Mean Hemoglobin (±SD) over Entire Study Period 
4.4 Dose Stabilization 
~Epoetin 
-a- Darbepoetin 
Table 7: Comparison of Median Number of Dose Changes (IQR) and Median 
Number of Weeks to Dose Stabilization (IQR) between Epoetin and Darbepoetin 
Arms 
Epoetin Darbepoetin p value* 
Number Dose Changes Run-In Phase 0 (0-1.75) 0 (0-0025) 00377 
(median, IQR) 
Number of Weeks to Stable Hb 4 (4-1 2) 4 ( 4-805) 0.429 
(median, IQR) 
Number Dose Changes Active Phase 2 (1-3) 2 (0-3025) 00843 
(median, IQR) 
*Mann-Whitney U test 
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4.4.1. Run-In 
The number of dose changes and the weeks required to achieve hemoglobin stability 
(three consecutive Hb values in the target range, measured every 2 weeks) was 
determined and compared between groups. The data was not normally distributed. In the 
epoetin group, the median number of dose changes was 0 with an interquartile range of 0-
1.75 and in the darbepoetin group the median number of dose changes was 0 with an 
interquartile range of 0-0.25 (Table 7). When compared using the Mann-Whitney U test, 
the difference was not significant (p=0.377). The median number of weeks required to 
reach hemoglobin stability was 4 in both groups (p=0.429) with an interquartile range of 
4-12 in the epoetin group and an interquartile range of 4-8.5 in the darbepoetin group. 
4.4.2. Active Phase 
The number of dose changes required to maintain hemoglobin in the target range during 
the active phase was determined and compared for each group. In the epoetin group, the 
median number of dose changes was 2 with an interquartile range of 1-3 and in the 
darbepoetin group the median number of dose changes was 2 with an interquartile range 
of0-3.25. There was no significant difference in the medians (p=0.843) when compared 
using the Maru1-Whitney U test (Table 7). 
4.5 Dose Conversion Ratio 
The dose conversion ratio was determined by dividing the average epoetin dose for each 
subject at the time of randomization by the average darbepoetin dose at three points in the 
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study- at the end of the run-in phase and at the 3 and 6 month intervals of the active 
phase. The mean dose conversion ratio at the end of run-in phase was 280:1 (95% CI 198-
362:1). At the 3 month point of the active phase it was 360:1 (95% CI 262-457:1). At the 
6 month point of the active phase it was 382:1 (95% CI 235-529:1). 
A similar calculation was performed for subjects in the epoetin arm to determine the trend 
in dose required over the study time in this group. The epoetin dose for each subject at the 
time of randomization was divided by the epoetin dose at the end of the run-in phase and 
at the 3 and 6 month intervals of the active phase. The ratio at the end of the run in phase 
was 1.1 :1 (95% CI 0.9-1.4:1 ), at the 3 month point of the active phase it was 1.2:1 (95% 
CI 0.6-1.9) at the 6 month point ofthe active phase it was 1.2:1 (95% CI 0.8-1.5) 
indicating that the epoetin doses were relatively stable. 
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Chapter 5 Discussion 
5.1 Study Design and Algoritlm1 Based Management 
There have been a number of observational switch studies, both prospective and 
retrospective, which have indicated that there may be a cost difference between 
darbepoetin and epoetin in the management of anemia in CKD. There is a lack of 
prospective, randomized controlled trials in this area. This research represents the first 
prospective, parallel group randomized controlled trial of intravenous epoetin and 
darbepoetin in hemodialysis patients with the primary outcome of cost. 
Strengths of this study design include a run-in period to allow initial dose stabilization 
and a subsequent 12 month follow up which would be adequate to attain complete dose 
stabilization in the darbepoetin arm after the switch. In addition, the study was conducted 
only in hemodialysis patients and all ESAs were administered intravenously before and 
after randomization. An important component of the study was the use of a standard 
validated algorithm for ESA and iron dosing in all subjects with changes made only by 
the study investigator. 
Numerous clinical guidelines have been published to direct the use of ESAs and iron.4' 7' 8 
Despite this, anemia often remains unrecognized and management is less than optimal. In 
a cross-sectional study of 8154 hemodialysis patients in the United States it was found 
that there was significant regional and patient-specific variation in anemia parameters. 
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Females, African Americans, patients 18-44 years of age and patients on dialysis for less 
than six months had significantly lower mean hemoglobin values despite having 
significantly higher epoetin doses than males, Caucasians, older patients and patients on 
dialysis for six months or more. There was also significant regional variation in the 
prescribing patterns for epoetin and iron.47 Brimble et al published a randomized 
controlled trial of protocolized anemia management in hemodialysis patients in which 
215 patients were randomized to anemia management with usual care or to management 
with an anemia management protocol. The primary outcome was the proportion of patient 
Hb values in the target range in the final 8 weeks of the 8 month study. The final 
proportions were not significantly different between the two groups (62% control, 63.6% 
protocol, p=0.8). There was however a significant difference in epoetin dose in patients 
who remained in the study for longer than 5 months, the epoetin dose in the protocol 
group was 2788 units weekly less than the standard care group (p<0.05), suggesting that a 
protocolized approach may provide similar results but with more efficient use ofESAs.48 
As anemia management is primarily a medication-related activity, clinical pharmacists 
are ideally positioned to develop and administer anemia management protocols.47• 49 
Pharmacist-implemented anemia management protocols have been found to provide 
significant clinical and economic benefits in a number of studies. 50-55 
In the Waterford Hospital Hemodialysis Unit of Eastern Health, a pharmacist managed 
anemia protocol has been in place since 2005. The protocol was developed by the clinical 
pharmacists in consultation with the Nephrologists of Eastern Health and it is updated 
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regularly to reflect current guidelines for ESA and iron use in hemodialysis patients. The 
current algorithms (Appendices A and B) have been used since 2009 and were developed 
using the most recent CSN guidelines 4 . Enrollment in this study began in the Fall of 2010 
and the first patients were randomized in December 2010, so the algoritlu11s were already 
being used in all patients at the Waterford for more than a year before the trial 
commenced. As part of the anemia management in this hemodialysis uni t, monthly data is 
collected for anemia targets and ESA dose for all patients. From January to December 
2010 the mean weekly epoetin alfa dose was 7715 units, the mean Hb was 109.6g/L and 
the mean proportion ofHb values in the target range (1 00-120g/L) was 74%. The mean 
proportion of TSAT values <20% was 16% and the mean proportion of serum fenitin 
values<200).lg/L was 11 %. The same algoritluns were used in the study protocol. This 
likely contributed to the hemoglobin stability seen throughout the trial, particularly in the 
run-in phase. 
5.2 Primary Outcome- Cost 
The analysis of the primary outcome of total ESA cost over 12 months demonstrated a 
significant difference with darbepoetin costing $1876 less per year per patient than 
epoetin. Considering the number of hemodialysis patients cunently being treated with 
ESA for anemia and the high cost, a difference per patient of $1876 would represent a 
significant cost savings to third party payers and to government. 
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The distribution of the total cost was not normal, so nonparametric analysis was used to 
compare medians. When the distributions were compared separately, it was found that 
epoetin costs were normally distributed but darbepoetin was not. In addition, there was a 
major outlier in the darbepoetin group in a patient who subsequently met the definition of 
ESA resistance. The analysis was run with this outlier removed to determine if it would 
change the distribution and it did not, the distribution of total cost for darbepoetin still had 
a large right skew. 
5.3 Anemia Targets 
It was important to determine if anemia targets were different between the two arms to 
validate any conclusions from the primary outcome data. If any of these were 
significantly different, it could account for a difference in required dose of ESA and 
subsequent cost. The main anemia indices used in clinical practice are Hb, serum ferritin 
and TSAT and in this study none of these displayed any statistically significant 
differences. In addition, ifthe dose of iron was different between the two anns it could 
account for a difference in ESA requirements so the mean weekly iron dose and total iron 
cost over 12 months were compared and these were not different. Both groups stayed 
within the target hemoglobin range over time with similar fluctuations when the mean 
hemoglobin was compared over the entire study period. Therefore, the difference in cost 
between epoetin and darbepoetin occurred when anemia management was comparable in 
both treatment groups. 
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5.4 Dose Changes 
Before entering the active phase of the trial , each subject had to demonstrate hemoglobin 
stability with three consecutive measurements within the target range. It was of interest to 
know if there was a difference in the time or number of dose changes required to achieve 
this stability, particularly when switching from epoetin to darbepoetin. The median 
number of changes required in the run-in phase was 0 in both groups with the 
interquartile range in epoetin group being 0-1.75 and in the darbepoetin 0-0.25, with no 
statistically significant difference. The number of weeks required to stabilize hemoglobin 
was also determined and again the difference between the two arms was not significantly 
different with a median of 4 weeks in each group. 
The number of dose changes required in the active phase to maintain hemoglobin within 
the target range was also determined and compared, as this would be an indicator of 
hemoglobin variability. The median number of changes in the epoetin group was 2 with 
an interquartile range of 1-3 and the median number of changes in the darbepoetin group 
was 2 with an interquartile range of 0-3.25. The medians were not significantly different. 
While this was a secondary outcome and the trial was not designed to determine 
hemoglobin variability, this would indicate that there may not be a difference between the 
two ESAs. It is of interest to note that based on the dose conversion ratios the eventual 
dose of darbepoetin required in most cases was lower than at the start (which would have 
necessitated dose changes), yet there were sti ll a comparable number of dose changes 
required in the epoetin arm where the overall dose remained relatively stable based on the 
ratios at the end of the run-in and at 3 and 6 months. 
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5.5 Dose Conversion Ratio 
As was stated in the introduction, the dose conversion ratio of epoetin:darbepoetin has 
been extensively studied and while most have found it to be higher than the initial 200:1 
ratio, there is much variability reported. It is generally agreed upon that predicting the 
dose conversion ratio is key to determining the relative cost of these agents. In an effort to 
estimate the dose conversion ratio in this study, it was calculated for subjects in the 
darbepoetin arm using the mean dose at the end of the run-in phase and at the 3 and 6 
month points of the active phase. The rationale for the 6 month measure is that it has been 
suggested based on previous studies and the half life of red blood cells that it requires 5-6 
months for patients to achieve a stable dose with darbepoetin. 19' 32 At the end of the run-in 
phase the mean dose conversion ratio was 280:1, at the 3 month point it was 360:1 and at 
the 6 month point it was 382:1 indicating that the dose ratio is likely greater than 200:1 
for most patients and this supports the finding of a cost advantage for darbepoetin over 
epoetin. This also supports the idea that the darbepoetin dose required does lessen over 
time when an initial 200:1 ratio is used to determine dose conversion from intravenous 
epoetin to intravenous darbepoetin, and dose stabilization is likely not achieved in the 
first few months. 
5.6 Limitations and Challenges 
It was challenging to enroll the desired number of subjects despite the number screened 
and the number found eligible. Of the 208 patients screened, 98 met one of the exclusion 
criteria. The most common reasons for exclusion were an inability to comprehend and 
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sign the consent document (20) or an intention to move to another centre (20). The 
number of patients unable to comprehend and sign consent is indicative of the 
demographics of the hemodialysis population, many of whom are elderly and in poor 
health with multiple comorbidities. A large number intending to move to another centre is 
the result of the distribution of hemodialysis units in this province. There are a several 
satellite dialysis units dispersed around the province, but most patients begin treatment in 
St. John's for medical reasons or while awaiting space in a satellite unit so at any given 
time there is a significant number of patients in the study centres that are planning to 
move soon. Intolerance to the intravenous iron product used in the study, Ferrlecit®, 
excluded another 16 patients. While iron intolerance is not uncommon, patients can often 
tolerate an alternate product (i.e. iron sucrose) however it was decided from the outset 
that it would be best to use only one iron product in the trial and this ultimately excluded 
sixteen potential subjects. In addition to these reasons, a number of patients (20) had 
characteristics which could lead to ESA resistance including high epoetin doses (2:250 
units/kg/week), malignancy, high PTH or ongoing infection. Thirty-four of the eligible 
patients declined to participate and the majority did not provide a specific reason but in 
general it was a concern of changing from their present therapy when they were currently 
feeling well. Again, many of these patients were elderly with multiple comorbidities. As 
these problems are common in all hemodialysis populations, recruitment for a trial like 
this will continue to be challenging. 
As presented earlier, the sample size calculated to detect a difference of $800 per patient 
per year for ESA with a 2-sided a=0.05 and power (1-~)=0 . 80 was 11 2 subjects. 
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Participation was less than expected for reasons outlined above and when it became 
apparent that the desired number would not likely be recruited in a reasonable time 
period, enrollment was completed after 50 subjects were randomized. With a sample size 
of 50 subjects, using a 2-sided a=0.05 and a power (1 -P)=0.80, a difference of $1215 per 
year per patient in ESA cost could be detected. 
Incomplete follow up occurred in a number of subjects. There were 8 cases and in each of 
these the last month's data was carried forward to the end and used in the analysis which 
could arguably create a bias. However if the increasing dose conversion ratio over time is 
considered, it would be expected that this carry forward method could potentially offer a 
bias favouring epoetin and not darbepoetin as one would expect the doses and cost of 
darbepoetin to decrease further in these patients if they had completed the 12 months. 
A potential limitation in generalizing these results is that this study excluded patients who 
often require the highest doses including those with ESA resistance and iron intolerance. 
It also did not include many patients who were unable to comprehend and sign the 
consent form. Proponents of retrospective observational switch studies argue that their 
results are more applicable to the "real-world" scenario than a trial such as this as more 
patients are included. In patients with ESA resistance and iron intolerance there would 
possibly be less of a cost difference between the two ESAs as they tend to require higher 
doses of epoetin and would likely require higher doses of darbepoetin as well. On the 
other hand, there is some evidence in the literature to support a higher dose conversion 
ratio at higher doses of epoetin and if this is the case, one would expect a potential cost 
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advantage with darbepoetin in resistant cases. With respect to the elderly and those unable 
to consent, this population is generally not different from the general dialysis population 
in their ESA and iron requirements so it is arguable that these results could be applicable 
in these patients. As a pre-defined dosing algoritlm1 was used in this trial , the results may 
not be generalizable to dialysis units without this approach to anemia management. This 
study was solely in hemodialysis patients receiving ESAs intravenously and therefore the 
results may not be the same in the non-dialysis CKD population or in groups where ESAs 
are administered subcutaneously. 
The primary outcome measured in this trial is drug acquisition cost and non-acquisition 
costs were not considered. As previously discussed, Churchill et al conducted a study of 
non-acquisition costs associated with ESA administration44and found a cost savings with 
the less frequent administration required by darbepoetin. Time and motion techniques 
were used to determine nursing time for preparation and administration of the ESAs. A 
comparison of non-acquisition costs coupled with the drug cost outcome in our study 
would provide a more accurate picture of total cost savings between epoetin and 
darbepoetin. In addition to time in motion studies of nursing staff, it would be useful to 
study time in motion and inventory control requirements for pharmacy staff as 
darbepoetin requires a smaller number of syringes per prescription and in turn lower 
maintenance inventory levels. While this would be of interest, there is no data to suggest 
that non-acquisition costs would negate the results of this study. 
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Chapter 6 Summary 
This study was undertaken to determine if there is a cost difference between epoetin and 
darbepoetin when used intravenously in the management of anemia of chronic kidney 
disease in hemodialysis patients. To date there have been very few head-to-head 
comparisons of the two ESAs and the question has not been clearly answered. Most 
studies have been pre- and post-conversion comparisons in which results are difficult to 
interpret due to the absence of a control group and the tendency for ESA requirements to 
change in hemodialysis populations over time. Many of the studies were of subcutaneous 
administration, whereas the intravenous route is most commonly used in hemodialysis 
patients now. This is the first parallel group, randomized controlled trial with dose and 
cost as a primary outcome using the intravenous route in hemodialysis patients. 
The results demonstrated that in this group of hemodialysis patients with comparable 
anemia management in both arms, darbepoetin cost $1876 less per year per patient than 
epoetin. With approximately 90% of hemodialysis patients receiving ESAs in this 
province, it represents a costly component of care. A difference of this magnitude 
represents a significant cost savings and would help clinicians, policy makers and payers 
to make rational decisions about the choice of ESA used in this population. 
The number of dose changes and the weeks required to achieve hemoglobin stability was 
compared between groups and found to be simi lar. There was no difference in the number 
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of dose changes required in the active phase. These results may indicate that there is no 
difference in the two ESAs with respect to hemoglobin variability. 
The dose conversion ratios found in this trial support the concept of a cost advantage with 
darbepoetin. The ratios increased at both the 3 and 6 month intervals which seems to 
indicate that dose stabilization with darbepoetin does require several months. 
A cost minimization analysis was conducted in an open label, parallel group, randomized 
controlled trial of fifty subjects. The results provide evidence for a cost advantage with 
intravenous darbepoetin alfa as compared to intravenous epoetin alfa in the management 
of anemia of chronic kidney disease in hemodialysis patients. 
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Appendix A: Eprex®/ Aranesp® (ESA) Dosing Algorithm 
Hemodialysis Anemia Management Algorithm 
ESA: Erythropoiesis 
Stimulating Agent (epoetin 
alpha or darbepoetin) 
ASSESS HEMOGLOBIN (Hgb) STATUS: Notify physician if Notify physician if 
Hgb> 150gA.. or increase Target: 11 Og/L Hgb<90gll or if fall in 
in Hgb> 20gll since last Acceptable Range 100-120g/L Hgb> 20gll since last 
bloodwork bloodwork I -
+ • + I Above Target and/or Large Increase in Hgb(>20) I I Hgb 100-120 and Stable I Hgb 99 or Lower and/or (no rise or fall >20) Fall ing 
j .. • Receiving ESA? I I Receiving ESA? I Receiving ESA? 
-
--
~ ~ 
----
--....__ 
NO YES I 
ESA on hold or discontinued I NO I I YES I NO YES 
.j --~ 
---
[Hgb 121-135 l I Hgb>i35 I (Hgb 126-135 I I Hgb 121-125 I 
• • + .. 
No ESA Reduce ESA HOLD ESA Continue to Rest art ESA No ESA Maintain Notify Increase 
required dose1' 1 Repeat CBC hold ESA: at 75% of dose required ESA dose physician ESA dose1' 1 
If dose in 2 weeks Repeat CBC in before hold for 
reduction in and reassess 2 weeks and Initiation of 
previous 4 reassess ESA 
weeks, 
maintain 
current dose 
l 
I ASSESS IRON STATUS- SEE PAGE 2 I 
1) ESA Titration: 10-25% increments except when : -Hgb increase is < 5g/Limonth, increase dose by 25-50% 
-Hgb increase is > 20g!L/month, decrease dose by 25-50% 
2) If epoetin alpha dose is >30 OOOut!week or darbepoetin>150mcg/week for 2 months or more and Hgb<11 Og/L notify Nephrologist 
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Appendix B: Ferrlecit® Dosing Algorithm 
has positi oe If patient 
bloodc 
therapy sh 
ultures, iron 
ou/d be held. 
TSAT>50% OR 
Ferritin >800m cg/L 
IRON OVERLOAD 
HOLD IRON 
reassess with next 
bloodwork 
ASSESS IRON STATUS 
Targets: TSAT 20-50% and Ferritin 200-SOOmcg/L 
(acceptable Ferritin range 200-SOOmcg/L) 
l 
NOTE If TSAT and Ferritin values indicate both an overload and the need for iron 
replacement (i .e. TSA T <20% and Ferritin>800mcg/L) contact physician for further orders 
I 
TSAT <20% OR TSAT 20-50% 
Ferritin<200mcg/L AND 
REPLACEMENT OF I FERRITIN 200-800mcg/L IRON STORES MAINTENANCE OF IRON STORES /~ 
IV lron13l with each If receiving If just completed If iron is currently 
maintenance iron : Iron replacement: on hold: 
hemodialysis to a Continue current Initiate Restart iron at 112 the 
total dose of 1000mg maintenance dose14' maintenance IV frequency but the 
Reassess iron status no iron(4 ) same dose as before 
sooner than 1 week after hold. This is the new 
last dose maintenance dose. 
\ 
If not receiving IV 
Iron : 
Iron replacement is 
not necessary 
~MonitotSAT monthly •nd Fe"it;n~ 
every 3 months 
3) Sodium ferric gluconate 125mg, Iron Sucrose or Iron Dextran 100mg . Give 25mg test dose if initiating Iron Dextran. 
4) Sodium ferric gluconate 62 5-125mg, Iron Sucrose or Iron Dextran 100mg every 1-4 weeks. Give 25mg test dose if initiating Iron Dextran. 
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Appendix C 
Memorial University and Eastern Health 
Consent to Take Part in a Clinical Trial 
TITLE: 
PROTOCOL TITLE: 
Study Doctors: 
Dr. Sean Murphy 
Dr. Brendan Barrett 
Dr. Bryan Curtis 
A study comparing the cost of two drugs used to treat 
anemia in patients with chronic kidney disease on 
dialysis 
A Randomized, Controlled Trial of Costs Associated 
with Anemia Therapy in Hemodialysis Patients Treated 
with intravenous Darbepoetin alfa versus Epoetin alfa 
Phone number: 
777-7226 
777-8073 
777-7226 
Researcher, Clinical Pharmacist: 
Andrea Woodland 777-3924 OR 777-3571 
Part A: General information 
Introduction 
You have been invited to take part in a research study. Taking part in this study is 
voluntary. It is up to you to decide whether to be in the study or not. You can 
decide not to take part in the study. Ifyou decide to take part, you are free to leave 
at any time. This will not affect your normal treatment. 
Before you decide, you need to understand what the study is for, what risks you 
might take and what benefits you might receive. This consent form explains the 
study. 
Please read this carefully. Take as much time as you like. lf you like, take it home to 
think about for a while. Mark anything you do not understand or want explained 
better. After you have read it, please ask questions about anything that is not clear. 
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The researchers will: 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
We do not know if taking part in this study will help you. You may feel better. On 
the other hand, it might not help you at all. It might even make you feel worse. We 
can't always predict these things. We will always give you the best possible care no 
matter what happens. 
You cannot take part in this research study if you are: 
• Taking part in another drug study at this time 
• If you have finished another drug study in the last 90 days 
• If you have been in another research study in the last year you should tell the 
study doctor. 
Part B. Explaining this trial 
1. Why am I being asked to join this study? 
You have been invited to take part in this study because your kidney disease has 
caused you to become anemic. This means that you have too few red blood cells in 
your blood. Red blood cells have hemoglobin which carries oxygen. You are 
already being treated with a drug - Erythropoietin - for this problem. 
Erythropoietin is a hormone made by the kidneys to help your body make red blood 
cells. When your kidneys cannot make enough of this hormone, you become anemic. 
This is common in patients with chronic kidney disease. 
Two types of Erythropoietin are available in Canada to treat anemia. One is epoetin 
alfa (trade name Eprex®) and the other is darbepoetin alfa (trade name Aranesp®). 
You are currently taking Eprex ® for your anemia. 
2. What is being tested? 
Eprex ® and Aranesp® are both approved for use in Canada and both seem to be 
equally effective for treating anemia. The cost of these drugs, however, may not be 
the same. It is difficult to compare them because they are dosed in different ways. 
This study will determine what the total costs are for each drug over a one year 
period. 
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3. How many people will take part in this study? 
If you agree to take part, you will be one of 112 patients who will join this study in 
this province. This study is only being done in Newfoundland. 
4. What is the purpose of this study? 
The purpose of this study is to determine and compare the total costs for each drug 
over a one year period. 
5. How long will I be in the study? 
The study will be about 14 to 18 months long. 
6. How is the trial being done? 
If you are suitable and volunteer for this study, you will be randomized (picked by 
chance like the toss of a coin) to one of two groups: 
1. Stay on Eprex ®, the drug you are currently taking 
2. Stop Eprex ®and switch to Aranesp® 
Aranesp® and Eprex ® will be given on dialysis through the machine just as you are 
currently receiving your Eprex ®. Eprex ® may be given once, twice or three times 
a week, depending on the dose. Aranesp® will be given once a week or once every 
two weeks, depending on the dose. Your red blood cell level will be kept the same 
regardless of the group you are in. 
Once you are randomized, you will know which group you have been put in. 
"Run-in" period (6 weeks+): 
Your red blood cell count must be in the correct range before we can collect data 
about the cost of your treatment. We will check your blood count (hemoglobin) 
every two weeks until it has been stable in the correct range for at least three 
measurements in a row. This will be done before your dialysis and blood will be 
taken through the machine. This means this part of the study will run for at least 
six weeks and possibly longer. 
Based on your red blood cell levels, or if side effects occur, your doctor may change 
the dose or stop either drug. Depending on the amount of iron in your blood, you 
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may also receive intravenous iron for all or part of the study since both drugs need 
iron to work well. The adjustment of drug dose and the use of intravenous iron will 
be done in the same way as currently standard in the care of patients requiring 
dialysis. 
"Active study" period (12 months): 
Once your red blood cell count is in the correct range and stable for six weeks we 
will be able to collect data regarding the cost of your treatment. Your blood count 
still still be measured every four weeks for the remainder of the study. You will not 
have to do any special tests, questionnaires, or surveys. If any important medical 
events occur we may ask you about this. 
7. What will happen if I take part in this trial? 
If you are selected for the Eprex® group, the only change in your treatment will be 
one extra blood count measurement per month during the "run-in" period. The 
amount of extra blood will be approximately one teaspoonful, taken through the 
dialysis machine tubes. Our current practice is to check blood levels once monthly; 
this will stay the same during the active study period. 
If you are selected for the Aranesp ® group, your prescription will be changed to 
this drug. Because of the nature of this drug you will only receive it once a week or 
once every two weeks, but your hemoglobin level will be kept the same. The number 
and type of blood tests will be exactly the same as the other group. 
8. Are there risks to the study? 
Switching from Eprex® to Aranesp® 
It is possible that your hemoglobin level will not be as well controlled on Aranesp® 
as it was on Eprex®, particularly in the early stages of this study. Your hemoglobin 
may become too low or too high, depending on your body's response. This can 
usually be corrected with a change in dosage. Every effort will be made to keep your 
hemoglobin in the usual treatment range. Your hemoglobin will be checked every 
two weeks during the run-in phase to ensure your hemoglobin stays in the correct 
range and prevent it from going too far outside of it. 
The chance of your hemoglobin becoming extremely high or low is very small. If 
your hemoglobin becomes extremely high, the drug may be stopped temporarily and 
some blood may be kept in the dialysis machine and thrown out after your 
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treatment. If your hemoglobin becomes extremely low you doctor may recommend 
a blood transfusion. It is very unlikely that these things will need to be done. 
Aranesp® and Eprex ® 
Both of these medications are approved by Health Canada and are widely used in 
people with kidney disease. You are already taking Eprex ®. Both drugs have 
similar possible side effects, including: 
• High blood pressure or worsening of your high blood pressure. This may 
happen if your red blood cell level rises too quickly (reported in less than 2% of 
patients). In this case, your doctor will lower your dose of study drug. 
• Rarely, very high blood pressures can result in headache, confusion, speech 
problems, or seizure (less than 1% of patients). This requires the immediate 
attention of your doctor in a hospital. If you have high blood pressure that is not 
well controlled, you will not qualify for this study. 
• Severe allergic reactions are rare but may be life-threatening (less than 1% of 
patients). 
• Rarely, (less than 1% of patients) patients have developed a reaction against 
erythropoietin (anti-erythropoietin antibodies) after treatment with approved 
erythropoiesis stimulating agents. In such patients, a condition called pure red cell 
aplasia (PRCA) can occur. This means that the red cells disappear slowly from the 
blood, as the bone marrow no longer makes them. The patient with PRCA becomes 
blood transfusion dependent, possibly for lifetime. 
• For patients with chronic kidney disease, drugs that help your body make red 
blood cells may increase the risk of heart attack, stroke, blood clots and death when 
red blood cell levels go above 120 g/L. During this study drug doses will be kept at a 
level to keep your red blood cell level at or below 120 g/L. This is standard practice 
at our institution. 
Please tell your doctor or the study staff right away if you think you are having side 
effects from your medication. 
Iron: 
Iron may be given to you through the study, as iron is required to produce red blood 
cells. Giving intravenous iron may be linked with the following side effects: 
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• common (1 or more in every 100 people): nausea, vomiting, diarrhea, 
headache, decreased blood pressure, dizziness, tiredness, back pain, joint 
pain, leg cramps, fever, swelling of lymph nodes 
• rare (1 or more in every 10,000 people): allergic reaction, hives 
• very rare (less than 1 in every 10,000 people): severe allergic reactions 
9. What About Pregnancy and Breast feeding? 
Women who are pregnant, or who intend to become pregnant or breastfeed will not 
qualify for this study. If you become pregnant during the study, you will have to 
stop participating in the study. 
10. Are there other choices? 
If you decide not to take part in this study, you will be treated as you currently are 
with no changes, with Eprex® once, twice, or three times a week to keep your 
hemoglobin stable. 
11. What happens at the end of the study? 
At the end of this study your doctor will discuss your treatment with you and advise 
the most appropriate drug for you. 
12. What are my responsibilities? 
If you take part in this study you will be expected to: 
• come to all your dialysis sessions as you normally would 
• follow the directions of the study doctor 
• report all medications that you are taking or plan to take 
• report any changes in your health 
• report any problems you think might be related to taking part in the 
study 
13. Can I be taken out of the trial without my consent? 
Yes. You may be taken out of the study at any time if: 
• the drug does not work for you 
• you do not follow the directions of the study doctor 
• if your study doctor feels side effects are harming your health 
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• there is new information which shows being in this study may not be 
in your best interest 
• you become pregnant 
• Health Canada or the ethics committee or your study doctor decides 
to stop the study 
14. What about new information? 
It is possible that we will get new information about a new treatment while 
you are in the study. You will be told about any new information that might 
affect your health or willingness to stay in the study. You will be asked 
whether you want to continue taking part in this trial. 
15. Will it cost me anything? 
Compensation 
You will not be paid to be in the study. The study drugs will be provided and 
billed the same way your Eprex® is now. If you are switched to Aranesp® 
and paperwork is required for your insurance company, we will take care of 
this before the switch happens. 
Research Related Injury 
The medicine you will take in this study has already been approved for use in 
Canada. In the event that you suffer injury as a direct result of taking part in 
this study, normal legal rules on compensation will apply. 
16. What about my privacy and confidentiality? 
Protecting your privacy is an important part of this study. Every effort to 
protect your privacy will be made. However it cannot be guaranteed. For 
example we may be required by law to allow access to research records. A 
copy of this consent will be put in your health record. If you agree, your 
family doctor will be told that you are taking part in this study. 
When you sign this consent form you give us permission to 
• Collect information from you 
• Collect information from your health record 
• Share information with the people conducting the study 
• Share information with the people responsible for protecting your 
safety 
Access to records 
The study doctor and members of the research team will see health and study 
records that identify you by name. 
Other people may need to look at your health record and study records and 
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information that identify you. This might include 
• the research ethics board for quality purposes 
• Health Canada 
They can look at your records only when one of the research team is present. 
Use of your study information. 
The research team will collect and use only the information they need to 
judge the safety and usefulness of the drugs. 
This information will include your 
• date of birth 
• sex 
• medical conditions 
• medications 
• the results of tests and procedures you had before and during the 
study 
• information from study interviews and questionnaires 
Your name and contact information will be kept secure by the research team 
in Newfoundland and Labrador. It will not be shared with others without 
your permission. Your name will not appear in any report or article 
published as a result of this study. 
Information collected for this study will kept as long as required by law. This 
could be 25 years or more. 
If you decide to withdraw from the study, the information collected up to that 
time will continue to be used by the research team. It may not be removed. 
After your part in this study ends, we may continue to review your health 
records. We may want to follow your progress and to check that the 
information we collected is correct. 
Information collected and used by the research team will be stored by the 
Patient Research Centre, Eastern Health. The Manager of the Centre is the 
person responsible for keeping it secure. 
Your access to records 
You have the right to see the information that has been collected about you. 
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17. What are my rights? 
Signing this form gives us your consent to be in this study. It tells us that you 
understand the information about the research study. When you sign this 
form, you do not give up your legal rights. Researchers or agencies involved 
in this research study still have their legal and professional responsibilities. 
You can talk to someone who is not involved with the study at all. They can tell 
you about your rights as a participant in a research study. This person can be 
reached through: 
Office ofthe Human Investigation Committee (HIC) at 709-777-6974 
Email: hic@mun.ca 
19. What about questions or problems? 
If you have any questions about taking part in this study, you can ask your 
doctor. You can also meet with the doctor who is in charge of the study here 
at this institution. That person is: 
Dr. Sean Murphy (709) 777-7226 
OR 
Andrea Woodland (709) 777-3924 
After you have signed this consent form, you will be given a copy. 
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Signature Page 
Study title: A Randomized, Controlled Trial of Costs Associated with Anemia Therapy In 
Hemodialysis Patients Treated with intravenous Darbepoetin alfa versus Epoetin 
alfa 
Name of principal investigator: Dr. Sean Murphy and Andrea Woodland 
To be filled out and signed by the participant: 
I have read the consent [and information sheet]. 
I have had the oppottunity to ask questions/to discuss this study. 
I have received satisfactory answers to all of my questions. 
I have received enough information about the study. 
I have spoken to Dr. and he/she has answered my questions. 
I understand that I am free to withdraw from the study 
I. at any time 
2. without having to give a reason 
3. without affect ing my future care 
I understand that it is my choice to be in the study and that I may not benefit. 
I agree that the study doctor, the study sponsor or a regulatory agency 
may read the parts of my hospital records relevant to the study. 
I understand how my privacy is protected and my records kept confidential. 
I agree to take part in this study. 
Please check as appropriate: 
Yes { }No {} 
Yes { } No {} 
Yes { } No { } 
Yes { } 
Yes { } 
Yes { } 
No{} 
No { } 
0 { } 
Yes { } No { } 
Yes { } No { } 
Yes {} No { } 
Yes { } No { } 
Signature of patticipant Name printed Year Month Day 
Signature of person conducting 
the consent discussion 
Signa/lire q( witness flf applicable} 
Month Day 
To be signed bv the investigator: 
Name printed Year Month Day 
Na111e printed Year 
l have explained this study to the best of my abil ity. I invited questions and gave answers. I believe that the 
participant fully understands what is involved in being in the study, any potential risks of the study and that 
he or she has freely chosen to be in the study. 
Signature of investigator Name Printed Year Month Day 
Telephone number: 




